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THE ROLE OF HSF1 PROTEIN REGULATION ON NEURODEGENERATION
Abstract
Cellular protein homeostasis is achieved by a delicate network of molecular chaperones and various
proteolytic processes such as ubiquitin–proteasome system (UPS) to avoid a build-up of misfolded
protein aggregates. The latter is a common denominator of neurodegeneration. Neurons are found to be
particularly vulnerable to toxic stress from aggregation-prone proteins such as α-synuclein. Induction of
heat-shock proteins (HSPs), such as through activated heat shock transcription factor 1 (HSF1) via Hsp90
inhibition, is being investigated as a therapeutic option for proteinopathic diseases. HSF1 is a master
stress-protective transcription factor which activates genes encoding protein chaperones (e.g. iHsp70)
and anti-apoptotic proteins. However, whether and how HSF1 is dysregulated during neurodegeneration
has not been studied. Here, we discover aberrant HSF1 degradation by aggregated α-synuclein (or αsynuclein-induced proteotoxic stress) in transfected neuroblastoma cells. HSF1 dysregulation via αsynuclein was confirmed by in vivo assessment of mouse and in situ studies of human specimens with αsynucleinopathy. We demonstrate that elevated NEDD4 is implicated as the responsible ubiquitin E3
ligase for HSF1 degradation through UPS. Furthermore, pharmacologically induced SIRT1-mediated
deacetylation can attenuate aberrant NEDD4-mediated HSF1 degradation. Indeed, we define the
acetylation status of the Lys 80 residue located in the DNA-binding domain of HSF1 as a critical factor in
modulating HSF1 protein stability in addition to its previously identified role in the transcriptional activity.
Together with the finding that preserving HSF1 can alleviate α-synuclein toxicity, the first part of the study
strongly suggests that aberrant HSF1 degradation is a key neurodegenerative mechanism underlying αsynucleinopathy. Chronic activation of another cellular stress response, unfolded protein response in ER,
has been implicated in tauopathy including Alzheimer’s disease (AD). The unfolded protein response
(UPR) in the endoplasmic reticulum (ER) and the cytoplasmic heat stress response are two major stress
response systems necessary for maintaining proteostasis for cellular health. Failure of either of these
systems, such as in sustained UPR activation or in insufficient heat shock response activation, can lead to
the development of neurodegeneration. Alleviation of ER stress and enhancement of heat shock response
through heat shock factor 1 (HSF1) activation have previously been considered as attractive potential
therapeutic targets for AD—a prevalent and devastating tauopathy. The second part of the study
concentrates on our attempts to understand the interplay of the two aforementioned systems and their
cooperative role in AD. We provide compelling in vitro and in vivo evidence that strongly suggests an autopropagating interplay of UPR activation and HSF1 degradation being a common pathogenic feature in
both human AD and tau transgenic mouse AD models. We identify aging-associated AD-like
neuropathological changes in the hippocampus of HSF1 heterozygous knock-out mice. We speculate that
HSF1 loss as an early (earliest) event which constitutes a mechanistic connection between ER stress and
tau hyperphosphorylation in tau pathology. Finally, we demonstrate that aged mice lacking HSF1 gene
exhibited deficits in hippocampal-dependent functions including short-term working memory, spatial
learning and long-term memory. All together, our work supports a previously underappreciated
importance of this master stress regulator HSF1 in neuronal functions and in maintaining brain
homeostasis.
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ABSTRACT
Cellular protein homeostasis is achieved by a delicate network of molecular
chaperones and various proteolytic processes such as ubiquitin–proteasome system (UPS)
to avoid a build-up of misfolded protein aggregates. The latter is a common denominator
of neurodegeneration. Neurons are found to be particularly vulnerable to toxic stress from
aggregation-prone proteins such as α-synuclein. Induction of heat-shock proteins (HSPs),
such as through activated heat shock transcription factor 1 (HSF1) via Hsp90 inhibition,
is being investigated as a therapeutic option for proteinopathic diseases. HSF1 is a master
stress-protective transcription factor which activates genes encoding protein chaperones
(e.g. iHsp70) and anti-apoptotic proteins. However, whether and how HSF1 is
dysregulated during neurodegeneration has not been studied. Here, we discover aberrant
HSF1 degradation by aggregated α-synuclein (or α-synuclein-induced proteotoxic stress)
in transfected neuroblastoma cells. HSF1 dysregulation via α-synuclein was confirmed by
in vivo assessment of mouse and in situ studies of human specimens with αsynucleinopathy. We demonstrate that elevated NEDD4 is implicated as the responsible
ubiquitin E3 ligase for HSF1 degradation through UPS. Furthermore, pharmacologically
induced SIRT1-mediated deacetylation can attenuate aberrant NEDD4-mediated HSF1
degradation. Indeed, we define the acetylation status of the Lys 80 residue located in the
DNA-binding domain of HSF1 as a critical factor in modulating HSF1 protein stability in
addition to its previously identified role in the transcriptional activity. Together with the
finding that preserving HSF1 can alleviate α-synuclein toxicity, the first part of the study
strongly suggests that aberrant HSF1 degradation is a key neurodegenerative mechanism
underlying α-synucleinopathy.
Chronic activation of another cellular stress response, unfolded protein response
in ER, has been implicated in tauopathy including Alzheimer’s disease (AD). The
unfolded protein response (UPR) in the endoplasmic reticulum (ER) and the cytoplasmic
heat stress response are two major stress response systems necessary for maintaining
proteostasis for cellular health. Failure of either of these systems, such as in sustained
UPR activation or in insufficient heat shock response activation, can lead to the
development of neurodegeneration. Alleviation of ER stress and enhancement of heat
shock response through heat shock factor 1 (HSF1) activation have previously been
considered as attractive potential therapeutic targets for AD—a prevalent and devastating
tauopathy. The second part of the study concentrates on our attempts to understand the
interplay of the two aforementioned systems and their cooperative role in AD. We
provide compelling in vitro and in vivo evidence that strongly suggests an autopropagating interplay of UPR activation and HSF1 degradation being a common
pathogenic feature in both human AD and tau transgenic mouse AD models. We identify
aging-associated AD-like neuropathological changes in the hippocampus of HSF1
heterozygous knock-out mice. We speculate that HSF1 loss as an early (earliest) event
which constitutes a mechanistic connection between ER stress and tau
hyperphosphorylation in tau pathology. Finally, we demonstrate that aged mice lacking
HSF1 gene exhibited deficits in hippocampal-dependent functions including short-term
working memory, spatial learning and long-term memory. All together, our work
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supports a previously underappreciated importance of this master stress regulator HSF1
in neuronal functions and in maintaining brain homeostasis.
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CHAPTER 1.

INTRODUCTION

Neurodegeneration
Neurodegenerative diseases are chronic and progressive disorders characterized
by selective and gradual neuronal loss in cognitive or motor systems in the brain. Such
diseases are incurable fetal diseases. The etiology and pathogenesis of neurodegenerative
disorders remain largely unknown. Characterization of disease specific markers and the
patterns of neuronal loss enabled us to classify neurodegenerative disorders. Specific
disorders include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s
Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD),
Motor neurone diseases, Spinocerebellar ataxia, and Spinal muscular atrophy.
The Two Most Common Neurodegenerative Diseases: Alzheimer’s Disease and
Parkinson’s Disease
AD known as the sixth leading cause of death in the United States is the only
disease among the top ten causes of death that currently has no prevention and cure. By
2050, the number of people aged 65 and older suffering from AD is estimated to triple
from 5.2 million in 2016 to 13.8 million (Alzheimers association, 2016). AD was first
described in 1906 by Dr. Alois Alzheimer. The hippocampus is the primary severely
affected area in AD undergoing drastic shrinkage due to neuronal loss. Numerous animal
studies suggest that an intact hippocampus is critical for learning and memory. The most
common initial symptom of AD is to have difficulty in acquiring new information.
Symptoms at the fully developed final stage include impairment of cognitive and memory
function, as well as deformed personality. Acetylcholinesterase inhibitors and NMDA
receptor antagonists are the two FDA-approved drugs showing small benefits for treating
cognitive problems.
PD is the second most prevalent neurodegenerative disease after AD. An
estimated 1.5 million people in the United States alone have PD. PD was first described
in 1817 by James Parkinson. The symptoms of PD include motor (e.g., treamor,
bradykinesia, rigidity, postural instability) and non-motor dysfunction (cognitive
impairment, depression, sensory dysfunction). The motor symptoms of PD are caused by
the selective loss of neurons in the substatia nigra that produce dopamine (a
neurotransmitter that helps purposeful movement), leading todepletion of dopamine in
the striatum (Davie et al., 2008). L-DOPA, a direct precursor to dopamine, and dopamine
agonists that have similar effects as L-DOPA can diminish (or alleviate) motor symptoms
to large degrees. Monoamine oxidase inhibitors cause increased levels of L-DOPA in the
striatum and therefore improve motor symptoms as well.
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Genetic Revolution
The identification of mutations in several genes has advanced our understanding
of the pathogenesis of neurodegenerative diseases. HD is a hereditary neurodegenerative
disorder of mid-life onset caused by aberrantly long poly-glutamine sequence as a result
of expansion of CAG triplet repeats in the huntingtin gene on chromosome 4. HD is
characterized by progressive cognitive decline and chorea. With the exceptions of polyglutamine diseases including HD, Spinocerebellar ataxia, and Spinal muscular atrophy,
many other neurodegenerative diseases are predominantly sporadic in nature which cases
involve multiple genetic and environmental factors playing key roles in their
pathogenesis.
Most PD cases are sporadic and only less than 10 % of patients are associated
with familial forms of PD. Whereas mutations in SNCA and LRRK2 genes cause
autosomal-dominant PD forms, mutations in Parkin, PINK, DJ-1 and ATP13A2 genes are
responsible for autosomal-recessive forms of PD. Among these mutations, SNCA, the
first gene identified in PD, encodes -synuclein, abundant cytosolic protein with 140
amino acids. Mutations in LRRK2 are found to be the most common genetic cause of
both familiar and sporadic cases of PD. AD can be grouped into four subcategories by
two major criterias, early onset or late-onset and sporadic or familial. People diagnosed in
thirties, fourties, and fifties fall into early-onset disease (EOD). It is estimated that less
than 5 % of all AD cases are EOD. The majority of AD cases are sporadic and only less
than 1% of all AD cases fall into familial AD (FAD). While the symptoms of early-onset
FAD and late-onset AD (LOAD) appear to be similar to each other, they may have
different underlying pathogenic mechanisms. Neurogenetists discovered from their
studies on early-onset FAD that there are three distinct genes that cause familial AD.
They are APP on chromosome 21, presenilin-1 on chromosome 14, and presenilin-2 on
chromosome 1. Although FAD is rare, the discovery of genetic mutations has made it
possible to identify and understand the pathogenic mechanism of AD. In addition to FAD
mutations, there is a risk factor first identified with its great impact on AD, a E4 genetic
variant of a gene located on chromosome 17 called Apolipoprotein E-e4 (APOE4).
APOE4 was first discovered in 1993 to be a genetic variant that increases the chance of
developing AD. Sporadic AD with unknown cause is considered to be largely attributable
to gradual accumulation of aging-associated malfunctioning in cellular system.
Protein Aggregates in Neurodegenerative Diseases: Proteinopathy
Proteinopathy refers to diseases caused by defects in protein synthesis, folding,
trafficking, or degradation in cells. Protein aggregation is a common hallmark of
neurodegeneration. Immunohistochemical staining of postmortem human brain, which
was first developed in 1980s, has enabled us to understand cellular changes in disease
states. One important discovery made by immunohistochemistry is the identification of
protein aggregates in neurodegenerative diseases. Intraneuronal aggregates such as
huntingtin, synuclein, and TDP-43 are found in PD, HD, and ALS, respectively, whereas
AD is known for having both intra- and extracellular aggregates. The first purification of
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neurofibrillary tangles (NFTs) and amyloid beta (A) in the brains of people suffering
from AD was described by Ihara et al., 1986 and Glenner and Wong, 1984, respectively.
As these proteins became the focus of AD research field, there were two groups of
scientists who each claimed that either tau or Ais more likely to cause AD. Now there
is growing evidence that tau protein may be a key driver of AD pathogenesis (Roberson
et al., 2007, Morris et al., 2011). Roberson and colleagues crossed A-forming APP
transgenic mice with Tau knock-out mice. Tau reduction prevented behavioral deficits
and premature mortality in APP transgenic mice. In addition, they demonstrated that tau
reduction increased resistance to excitotoxin-induced seizures.
As of the progressive characteristic of AD, plaques and tangles gradually spread
throughout the brain via synapses. It has been highlighted that proteinopathy may
underlie the prime mechanism responsible for the spread of neurodegeneration. In order
to appropriately target the toxic species, which forms of A and tau are synaptotoxic
species needs to be determined. The relative role of soluble protein versus insoluble
aggregates needs to be accurately identified. Whether protein aggregates themselves are
pathogenic or as incidental or beneficial response still remains as an open question in the
field.
Synucleinopatahy. Monomeric -synuclein (α-syn) is intrinsically disordered
protein that lacks a fixed stable structure with an approximate size of 14 kDa. This
protein can acquire α-helical secondary structure only upon binding to lipid vesicles. synmainly found in presynaptic terminals can interact with synaptic vesicles by binding
to membrane via its N-terminal domain consisting of seven of the 11-residue repeats
(Jensen et al., 1998, McLean et al., 2000). The physiological function of α-syn was
demonstrated in α-syn knock out mice to be involved in synaptic plasticity and synaptic
vesicle homeostatsis (Cabin et al., 2002). Mice lacking -syn gene showed impaired
spatial learning and memory (Kokhan et al., 2012). The aggregation propensity of -syn
can be accelerated by three point mutations of human -syn, A53T, A30P, and E46K,
that are known to be autosomal dominant and linked to early-onset PD (Polymeropoulos
et al., 1997). These mutations are located in the N-terminal repeats to which synaptic
vesicles bind and suppress -syn binding to vesicles, leading to loss of -syn function
(Jensen et al., 1998). -syn purified from mammalian cells exists as a stable helical
tetramer with an apparent size of 58–60 kDa (Bartels et al., 2011). Various forms of
physiological -syn (60-, 80-, 100- kDa multimers) were later found to exist in freshly
biopsied normal human brain specimen (Dettmer et al., 2015). Of note, tetrameric -syn
is more likely to resist aggregation than unfolded -syn monomer (Bartels et al., 2011,
Dettmer et al., 2015). It turned out that expression of -syn multimers was decreased in
hA53T mice and A53T iPSC neurons (Dettmer et al., 2015).s a result, -syn
aggregation is expected to produce neurotoxicity through a gain of function mechanism.
Synucleinopathy refers to a class of diseases associated with abnormal deposition
of -syn protein. Synucleinopathy is a major class of neurodegenerative diseases
including PD, dementia with Lewy bodies (DLB), and multiple system atrophy. In
synuclenopathy, -syn is found to abnormally polymerize into fibrils, forming the
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patholgocial inclusions such as Lewy body, and Lewy neurites. Lewy body represents
intracellular spherical masses composed of not only -syn but also other proteins such as
ubiquitin and neurofilament protein. Whereas PD primarily affects dopaminergic neurons
in the midbrain, Diffuse Lewy body disease, also called Lewy body dementia, has Lewy
body inclusions mainly in cortical neurons.
There is a hypothesis devised to explain the regional patterns of synuclein
pathology, which is called Braak staging of PD. Based on the varying degrees of
synuclein pathology, Braak and his group proposed a temporal sequence of events
occurring in PD brain (Braak et al., 2002). In stage 1, synuclein pathology is limited to
medulla oblongata or the olfactory bulb. In stage 2, rostrally adjacent structures including
the caudal raphe nuclei and the locus cerulues are additionally included. Stage 3 includes
the brain regions of amygdala and substantia nigra. Neuronal loss accompanied with
synuclein pathology starts to be detected in substantia nigra from stage 3 or 4. However,
a pitfall in the Braak staging scheme is that it cannot define where PD begins. Patients
with LRRK2 mutation, an autosomal-dominant PD mutation, do not display Lewy body
pathology except for the cases of G2019S LRRK mutation (Burke et al., 2008). In
addition, it is not tenable to assume that the presence of synuclein deposition necessarily
correlates with neuronal death. Rather, an inverse relationship between aggregate
formation and neuronal toxicity was demonstrated in human PD brain, Drosophila PD
model and in vitro HD model (Arrasate et al., 2004, Chen et al., 2005). Taken together, it
should be considered that Lewy body solely may not be a reliable indicator of cellular
dysfunction manifested in PD.
Tauopathy. Tau, mostly located in axons of neurons, is a microtubule binding
protein responsible for microtubule assembly and axonal transport in neurons. The
MAPT gene in chromosome 17q21 encodes tau protein. As a result of alternative splicing
in exons 2, 3, and 10 of the MAPT (microtubule-associated protein tau) gene, six
isoforms of tau have been identified in human brain, ranging in size from 352 to 441
amino acids. The N-terminal inserts are coded by exons 2 and 3, resulting in tau isoforms
with 0N, 1N, and 2N. Each exon of 9, 10, 11, and 12 encodes a microtubule binding
motif, and the existence of exon 10 is a determining factor between the three 3R (3
repeated domains) tau isoforms and the other three 4R (4 repeated domains) tau isoforms.
The binding ability of 4R tau to microtubules is stronger than that of 3R tau. 3R and 4R
tau contribute almost equally to total human tau. 1N3R and 1N4R are known to be the
most abundant forms in human brain. In AD, increase in 4R and/or decrease in 3R results
in approximately 2:1 4R:3R ratio. Considering 45 serine, 35 threonine, and 5 tyrosine
residues in the total 441 residues of tau protein, tau phosphorylation is a very complex
process. Regulation of tau isoforms and tau phosphorylation are the two major
mechanisms of controlling the proper functioning of tau protein. In contrast to
physiological forms of tau, pathologically hyperphosphroylated tau called paired helical
filament (PHF)-tau is dissociated from axon and forms insoluble fibrillary inclusions
called neurofibirallray tangles (NFTs) that highly accumulate in neuronal soma and
dendrites, leading to neuronal degeneration. Change in tau distribution from axonal to
dendritic spine is one early key event in AD brain (Kosik et al., 1989).
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Tauopathy is characterized by a build-up of tau aggregates which underlies the
pathogenic mechanisms of a number of neurodegenerative diseases. Tauopathy is not
limited to AD pathology. Tau protein is frequently found in α-syn positive inclusion
(Arima et al., 1999, Ishizawa et al., 2003). Tau and α-syn that co-exist in various
pathological conditions appear to accelerate the fibrillization of each other in vitro and in
vivo (Kotzbauer et al., 2004, Moussaud et al., 2014). Tauopathy includes Frontotemporal
dementia (FTD), the second or third most common type of dementia that accounts for
less than 5 % of all dementia. Approximately 50-70 % cases of FTD are sporadic, and 2040 % cases account for familial FTD. Only 10 % cases are inherited FTD with a clear
familial history of disease being passed down from the parents. The primary genes linked
to FTD are tau and progranulin. Around 30 % of inherited FTD are caused by mutations
in the tau gene. Other rare genetic causes of FTD include transactive response DNA
binding protein (TDP), valosin-containing protein, FUS, and sequestosome 1.
Frontotemporal lobar degeneration (FTLD) is a pathological term for FTD. Depending on
the feature of protein aggregates, it can further be categorized into FTLD-Tau, FTLDTDP (or FTLD-U), and FTLD-FUS. Pick’s disease is one type of FTD syndrome and a
rare form of progressive dementia that only affects certain areas of the brain, such as
frontal and temporal lobe, distinct from AD that progressively and broadly targets the
brain. Whereas memory loss is the earliest and primary symptom of AD, personality
change is an early symptomatic characteristic of Pick’s disease. Tau deposits found in
pick’s disease are mostly composed of 3R tau.
Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17)
is an autosomal dominant neurodegenerative disease that likely accounts for only a small
percentage of FTD. The symptoms of this disorder include behavioral and personality
disturbances, cognitive deficits, and motor dysfunction. The name of the disease is coined
for mutations in the tau gene located in chromosome 17 that are found in human FTDP17 patients. It is a very rare disease that 38 tau genetic mutations have been identified
over 100 families. The mutations found in the tau gene are either coding site or intronic
mutations. Intronic mutations largely located in intron between exon 10 and 11 influence
the exclusion (or inclusion) of exon 10, affecting the ratio of 4R- to 3R tau. About 90 %
of coding mutations with missense or deletion changes are located in the C-terminal end
of tau, altering the function of tau. Some mutations located in exon 10 likely lead to the
proportional increase of 4R to 3R tau. P301L mutation in exon 10 is the most prevalent
mutant form found in FTDP-17 patients.
Despite the absence of tau mutation that causes familial AD, our understanding of
tau pathogenesis has been advanced by identification of tau mutations in FTDP-17
patieints. Based on FTDP-17 mutations, several tau pathogenic mouse models have been
genetically engineered and characterized in recent years. The presence of NFTs in these
mouse models has enabled us to identify mechanisms by which pathogenic tau
contributes to AD progression. The difference in the tau gene between murine and human
is that murine tau only has 4R domain, and there are 14 amino acids differring in the Nterminal domain between them. Two decades ago, a tau transgenic mouse expressing the
longest human tau isoform was first generated and reported to exhibit mis-localized and
hyperphosphorylated tau protein (Götz et al., 1995). Human tau protein expressed in this
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mouse model was considered as pre-tangle form, not NFTs, as they did not form any
insoluble tau aggregates. The limitation of such transgenic mouse ooverexpressing only
one isoform was overcome by Duff et al., 2000. They generated tau transgenic mouse
model expressing all six isoforms of human tau transgenes acquired from the human P1derived artificial chromosome. Three years later, the same group circumvented any
potential effect of endogenous murine tau by establishing human tau gene overexpression
in the tau knock-out mice. These mice developed somatic accumulation of
phosphorylated tau by 3 months of age, and at 6 months of age, inclusions thought to be
NFTs were detected (Andorfer et al., 2003).
Later, Santacruz et al., 2005 created rTg4510 transgenic mouse model that
overexpresses mutant tau P301L gene (4R/0N) which is constitutively expressed until
inactivated by doxycycline administration. Pre-tangles began to form as early as 2.5
months. At 4 months of age, inclusions similar to NFTs appeared in the cortex and
significant neuronal loss (~ 60 %) was detected in the hippocampus (Santacruz et al.,
2005). Cognitive impairment became manifest at 2.5 ~ 4 months of age by morris water
maze (Ramsden et al., 2005). It is still under debate whether NFTs initiate neurotoxic
events or it can be a protective response of segregating harmful oligomers from executing
their function. By using tetracycline inducible expression system, Santacruz et al., 2005
provided a new insight on clear dissociation of neuronal loss and NFTs, suggesting that
NFTs alone are not sufficient to cause neurodegeneration and cognitive deficits.
Subsequently, Tau P301S (PS19) transgenic mouse was generated to overexpress 4R/1N
isoform of P301S tau under the control of prion promoter. Slight synaptic loss in 3
month-old PS19 preceded the filamentary tau inclusions at 6 months of age at which
spatial memory deficits were observed in morris water maze, followed by severe
neuronal loss at 9 months of age (Yoshiyama et al., 2007).
Recently, rTgTauEC was generated to express human tau P301L mutation
preferentially in the entorhinal cortex. Trans-synaptic tau propagation was revealed in the
brain of rTgTauEC where tau pathology spreaded from entorhinal cortex to functionally
connected neighboring brain regions. At 3 months of age, misfolded tau was detected by
Alz50 staining in the entorhinal cortex of rTgTauEC (de Calignon et al., 2012). Gallyas
silver-positive paired helical filaments, and both thioflavin S positive tangles and
neuronal loss, were observed in the rtgTauEC at 18- and 24-months of age, respectively
(de Calignon et al., 2012). There was no dramatic behavioral deficit in this mouse model.
Polydoro et al, 2014 indicated that impairment of electrophysiological properties such as
a decrease in LTP occurred even before tangle formation in rTgTauEC. More recently,
APP/PS1/htau transgenic mice were generatedto incorporate human AD genetics without
overexpression of mutation in disease-linked proteins. This mouse model successfully
recapitulated late-onset AD pathology by displaying age-dependent pathological changes
such as A plaque formation and tau hyperphosphorylation, and behavioral changes
including exaggerated fear response and motor deficits (Guo et al., 2013).
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Protein Quality Control and Stress in Neurodegeneration
Research on neurodegenerative diseases has focused on identifying the causes of
developing misfolded protein aggregates in the brain and how it could be prevented or
reduced for treating these devastating diseases. Despite clinical classification of AD and
PD as distinct entities, the concept that they may share common genetic and pathogenic
mechanism has been emerged and supported by numerous studies (Golde et al., 2013,
Moussaud et al., 2014). It should be noted that protein aggregation, a common hallmark
of neurodegenerative disease, could result from a failure of cellular defense system called
protein quality control. Protein quality control is a collective term to describe cellular
pathways that function in maintaining proteostasis. It is involved in ensuring proper
protein folding, sensing damage of proteins, and promoting clearance of damaged
protein.
Proteostasis is often challenged by various kinds of cellular stressors. In
particular, proteotoxic stress refers to cytotoxic stimuli that increase the fraction of
protein that are in an unfolded state, increasing the probability of forming aggregates. It
includes stress conditions such as heat shock, oxidative stress, calcium dysregulation, and
proteasome inhibition. In response to misfolded protein, stress response is activated to
cope with proteotoxic stress.
Stress is not merely one of conseuqences of toxic events, but rather it might play a
causative role in neurodegeneration. Even early life time experience of stress promoted
-amyloid plaque deposition in aged primates. (Merrill et al., 2011). There is an
interesting model, namely “a stressor-threshold model of selective neuronal
vulnerability”, describes the relevance of stress to neuronal death. According to this
model, gradually increasing stress differentially affects stress-resistant and stressvulnerable neurons, which may underlie the etiology and progression of
neurodegenerative diseases (Saxena et al., 2011). Compared to stress-resistant neurons,
stress-vulnerable neurons tend to form a vicious cycle of increasing intracellular stressor
load, which results from low threshold to interrupt cellular homeostasis processes.
Aggregation and propagation of toxic species may eventually affect other less vulnerable
neurons to increase their stressor load.
Consequently, disrupted proteostasis leads to proteotoxicity originated from
misfolded proteins, which causes impairment of cellular function. Proteotoxic proteins
are usually disease-linked proteins that when mutated produce aggregates and result in
neurodegeneration, such as prion, tau, A, and synuclein. Proteotoxicity is especially
detrimental to neurons in the brain with poor regenerative capability (Morimoto et al.,
2008). The mechanism underlying the failure of proteostasis is not clearly understood.
There is growing evidence that restoration of degradative machinery and enhancing the
activities of chaperones alleviate proteotoxicity derived from dysregulated proteostasis.
Herein, we will discuss various types of cellular protective system to cope with cellular
stresses and their role in neurodegeneration.
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Cellular Stress Response (Heat Shock Response)
After Italian geneticist Ferruccio Ritossa found a puffing pattern of chromosome
in response to heat stress in Drosophila in 1962 (Ritossa et al., 1962), in 1974, this
puffing could be explained by the discovery of an induction of selective genes now
called heat shock proteins (Schlesinger et al., 1990). Not only heat but also other
chemical stress that results in denaturing proteins (proteotoxic stress) could increase the
synthesis of heat shock proteins. Heat shock proteins are named according to their
molecular weight. They are generally referred to as stress protein (stress-responsive
gene). Evolutionarily, heat shock response is a highly conserved stress response. On the
other side, in 1976, the term of chaperone was first coined for nucleoplasmin that assists
in the correct assembly of nucleosomes by preventing the aggregation of histones with
DNA. Later, the usage of the term cwas extended to a subset of proteins whose main
function is to help correct folding of newly synthesized proteins and the assembled
subunits (Ellis et al., 1987). Many heat shock proteins turned out to have chaperone
activity that participates in correct (re)folding of proteins that are new or damaged from
cellular stress (Schlesinger et al., 1990). Unlike other cell types, heat shock response is
considered to be attenuated in neurons (Marcuccilli et al., 1999). Non-neuronal cells in
the brain such as glial cells showed significant Hsp70 induction after heat stress, which
was not observed in neurons (Pardue et al., 1992). Primary cultured hippocampal neurons
failed to turn on the transcriptional activity of HSF1 under stress (Marcuccilli et al.,
1996). Therefore, the existence of heat shock response in the rat hippocampus
homogenates (Higashi et al., 1995) may be attributable to the ability of glial cells, not
neurons, to activate HSF1 (Marcuccilli et al., 1996). Stress response involves not only
gene transcriptional activation but also promoting the degradation of malformed proteins
through ubiquitin proteasome system.
Ubiquitin Proteasome System and Neurodegeneration
Ubiquitin proteasome system (UPS) is one of the major proteinase complexes
responsible for selective degradation of many short-lived small proteins in eukaryotes.
UPS is a key controller of gene transcription because of its ability to degrade cyclins and
transcription factors. Its neuroprotective feature is attributed to the function in degrading
misfolded proteins as a result of stress. Substrate proteins targeted by UPS should be
conjugated with ubiquitin (Ub) via three consecutive steps; E1, ubiquitin activating
enzyme, adenylylates ubiquitin, followed by its transfer of ubiquitin to cystine residue of
E2, ubiquitin conjugating enzyme. Lastly, ubiquitin can be conjugated from E2 to
substrate protein by E3, ubiquitin ligase that recognizes its substrate and catalyzes the
degradation process. Intracellular protein with K48-linked poly-ubiquitin chains is likely
to be recruited to proteasome for its degradation. In contrast to polyubiquitination that
acts as targeting signal toward proteasome, monoubiquitination has been considered as to
spatially regulate protein activity by controlling protein localization and trafficking.
Substrates containing K48-linked ubiquitin chains are usually degraded by the 26S
proteasome, whereas those containing K63-linked chains may undergo a number of
different processes, including trafficking and/or lysosomal degradation. In particular,
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ubiquitin ligase NEDD4 (neural precursor cell expressed developmentally downregulated protein 4) was first reported as potential modifier of -syn pathology (Davies et
al., 2014). A NEDD4 family of E3 ligase consists of 9 members (NEDD4, NEDD4-2
(NEDD4L), ITCH, SMURF1, SMURF2, WWP1, WWP2, NEDL1, and NEDL2) highly
conserved in eukaryotes. It is characterized by three functional domains: C2 domain, 2-4
WW domains, and a HECT-type ligase domain. NEDD4 represents an ancestral member
of the family. NEDD4 has several important substrate proteins crucial for normal CNS
function such as PTEN, IGF- and AMPA receptor (Yang et al., 2010). Kwak et al., 2012
reported that endogeneous NEDD4 protein levels were significantly increased in human
neurodegenerative diseases patients including PD.
There has been substantial evidence of UPS impairment in synucleinopathy and
other neurodegenerative diseases (Keller et al., 2000, Chen et al., 2006). The first hint on
the link between UPS and neurodegeneration is that protein aggregates like NFTs highly
comprise Ub-conjugated proteins (Koo et al., 1999). Intracellular inclusion bodies found
in AD contain a mutant variant of ubiquitin called UBB+1 (raak et al., 1991). UBB+1
quite stable in neurons is not degraded by UPS. Lewy bodies, a hallmark of
synucleinopathy, consist of highly ubiquitinated -syn. Brains of both human -syn
transgenic mice and human PD patients display proteasomal dysfunction (Chen et al.,
2006). Post-translational modification of UPS subunits may account for a significant
decrease in UPS activity in the hippocampus of AD compared to control brain (Keller et
al. 2000). Tg2576 amyloid transgenic AD mouse model exhibited decreased UPS activity
(Oh et al., 2005). Recently, Myeku et al., 2016 provided a new evidence of tau-mediated
26S proteasome dysfunction regulated by cAMP-protein kinase A. Impairment of UPS
took place even before the formation of inclusion bodies, which suggests a possibility
that intermediate forms of protein aggregates may be sufficient to disrupt UPS function
(Bennett et al., 2005).
Cellular Stress Response in ER and Neurodegeneration: Unfolded Protein Response
(UPR) as a Result of ER Stress
As the major function of endoplasmic reticulum (ER) is protein folding and
synthesis, ER should be highlighted as a key intracellular place regulating the
proteostasis inside cells. Its role in protein synthesis for seceretory, membrane and
organelle-directed proteins are responsible for approximately 30 % of total proteome. In
response to the burden of unfolded proteins in the lumen of ER, ER can initiate its unique
stress response called unfolded protein response (UPR). UPR is initially initated to
restore ER homeostasis. In ER membrane, three ER sensor proteins (PERK, IRE1α,
ATF6) are present that send intracellular activation signals in each of distinct signaling
pathways to control transcription and translation during ER stress (Schröder and
Kaufman, 2005). In the absence of ER stress, HSP70a5 (BiP/GRP78), a Hsp70 family
protein in ER, inhibits UPR activation via its physical binding to PERK (Bertolotti et al.,
2000). Whereas UPR is initially trigered as an adaptive response to the disturbances in
ER homeostasis, inducing molecular chaperones such as Hsp70a5 (BiP/GRP78),
sustained chronic UPR activation as a result of unresolved ER stress eventually promotes
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cell death by inducing pro-apoptotic proteins such as CHOP primarily through the PERKeIF2-ATF4 pathway.
The presence of ER stress has been continuously identified in the cellular/animal
models and human studies for all the major neurodegenerative diseases (Matus et al.,
2011). Inconsistencies in the existence and functional outcome of UPR have been
reported among studies from distinct mouse models of neurodegeneration. This is
partially owing to the different methods used to assess UPR activation and difference in
mouse age and tau transgene. Phosphorylation of both eIF2 and PERK was highly
detected in the substantia nigra of human PD, not in control cases (Hoozemans et al.,
2007). Furthermore, PERK activation not only co-localized with NFTs but also
significantly correlated with hyperphosphorlyated tau in the human AD brains
(Hoozemans et al., 2005, Jeroen et al., 2009). Human brain specimens of other
tauopathies such as FTD showed UPR activation (Nijholt et al., 2012). While PERK was
activated in rTg4510 tau transgenic mice (Abisambra et al., 2013), APP transgenic
Tg2576 mice did not show any sign of UPR activation (Lee et al., 2010). Therefore, it
suggests that UPR activation observed in human AD brain may occur as a result of
abnormal tau aggregates, independent of amyloid beta deposits.
Several studies demonstrate that protein aggregates have potential to disrupt ERrelated basic cellular functions that induce UPR. verexpressed -syn considerably
blocked ER-Golgi trafficking, which was rescued by modifying the ER-Golgi trafficking
component gene, Rab1 (Cooper et al., 2006). During ER stress, in parallel with UPR, ER
induces endoplasmic-reticulum-associated protein degradation (ERAD), a cellular
pathway for targeting misfolded protein to the proteasomal degradation. Abisambra et al.,
2013 provided an evidence that overexpressed human tau P301L impaired ERAD and
induced UPR. Mutant tau was physically associted with ERAD heterocomplex VCP and
HRD1 in rTg4510 tau transgenic mice. As a result, ERAD substrate proteins failed to be
properly degraded and therefore accumulated in rTg4510 and human AD brain.
Conversely, UPR activation seems to play a causautive role in tauopathy.
Chemically induced ER stress led to tau hyperphosphorylation possibly mediated by
GSK3 activation (Sakagami et al., 2013). Furthermore, UPR activation may contribute
to tau accumulation by interrupting binding of tau to CHIP E3 ligase and inhibiting its
proper degradation (Sakagami et al., 2013). Genetic deletion of PERK prevented deficits
in both synaptic plasticity and spatial memory in APP-PS1 AD mouse model (Ma et al.,
2013). Thus, it is likely that chronic UPR activation eventually contributes to synaptic
dysfunctions manifested in AD. Hoglinger et al., 2011 showed the association of
polymorphisms in the EIF2AK3 locus, a gene encoding PERK, with progressive
supranuclear palsy, revealing a genetic linkage between UPR activation and tau
pathology. Given its complexity of displaying both protective and apoptotic effects
depending on the cellular context, it is necessary to understand which part of the UPR is
desirable to target and at what particular stage of disease progression.
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Autophagy-Lysosomal Pathway and Neurodegeneration
Autophagy is an essential degradation process for proper turnover of long-lived
proteins and entire organelles, such as mitochondria, inside the cell. Constitutively active
autophagy is highly required for neuronal survival as its failure itself could initiate
formation of ubiquitinated inclusion bodies and potentiate neuronal loss (Hara et al.,
2006). Autophagy can be strongly induced by heat- and ER stress to promote a clearance
of misfolded proteins, which is thus considered a neuroprotective mechanism (Ogata et
al., 2006, Zhao et al., 2009). Stress-responsive transcription factor HSF1 is actively
involved in autophagosome formation by binding to Atg7 promoter for transactivation
(Desai et al., 2013). During ER stress, autophagosome formation was mediated by IRE1JNK pathway (Ogata et al., 2006). Similar to UPR, autophagy is a protective response
under mild stress but it triggers cell death in extreme conditions. It is important to
recognize that the consequence of autophagy activation is largely determined by the
specific mediator of autophagy active in the cellular context.
There are three subtypes of autophagy: macroautophagy, microautophagy, and
chaperone-mediated autophagy, all of which are involved with autophagy-related genes
(ATGs) and associated enzymes. Chaperone-mediated autophagy (CMA) is a very
specific pathway where Hsc70 complex binds to specific substrates via recognition site
(KFERQ-like sequence) followed by binding of these substrate/chaperone complex to
LAMP2A receptor in the lysosome for degradation. However, macrophagy is a nonspecific, bulk degradation process that involves the formation of autophagic vacuoles that
finally fuse with lysosome, called autophagolysosomes. mTOR is a critical regulator of
autophagy induction, and autophagy is known to be suppressed by mTOR activation that
could be released by stress-related kinase AMPK signaling. Three downstream kinases
such as ULK1, ULK2, and ULK3, could induce activation of Class III PI3K complex
containing Beclin 1, the mammalian orthologue of yeast Atg6. ATG is the unified
nomenclature for naming yeast genes involved in non-selective autophagy (Ohsumi et al.,
2014). Currently, 37 ATG genes have been identified in yeast, and these genes seem to be
highly conserved from yeast to human. A family of ATGs are involved in the specific
steps in autophagy induction and cytoplasmic sequestration. Atg5 and LC3 II complexes
regulate autophagosome formation. During autophagy, a cytosolic form of LC3 I is
conjugated to phosphatidylethanolamine to form LC3 II which is further recruited to
autophagosomal membranes.
Initial identification of autophagosome accumulation in the patient brains with all
major neurodegenerative diseases suggests a possibility that autophagy impairment
contributes to the pathogenesis of proteinopathy (Wu et al., 2011). The central role of
autophagy in maintaining proteostasis has subsequently been demonstrated by studies
from several mouse models and human brain. Mice lacking Atg5 gene developed
cytoplasmic inclusion bodies and motor deficits (Hara et al., 2006). Genetic inhibition of
Beclin1 exacerbated amyloid pathology by accelerating both intracellular and
extracellular amyloid beta deposition in APP transgenic AD mouse model (Pickford et
al., 2008). Consistently, reduced Beclin1/Atg6 levels were detected in the post-mortem
human AD brain tissues (Pickford et al., 2008). Enhancement of autophagy by
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rapamycin, an inhibitor of mTOR, attenuated AD-like deficits in V717F APP mouse
model (Spilman et al., 2010). To achieve a goal of clearing proteins encaptured by
autophagosome, in addition to proper function of autophagosome formation, sufficient
lysosomal biogenesis and function should be equally considered. Expansion of the
lysosomal system found in early stages of AD brain might be a compensatory protective
response (Barrachina et al., 2006, Khurana et al., 2010). Lysosomal structural protein
LAMP1 in the limiting lysosomal membrane was upregulated in the human AD brains
and AD mouse models (Barrachina et al., 2006). It is notable that there was negative
correlation between LAMP1 expression and hyperphosphorylated tau accumulation in
individual cortical neurons in human AD brain, suggesting a decrease in LAMP1
expression upon the formation of tangles resistant to degradation (Barrachina etal., 2006).
Polymorphisms in a gene encoding Cathepsin D, a lysosomal aspartyl protease, have
been associated with AD onset (Papassotiropoulos et al., 2000). Lysosomal dysfunction
as a result of cathepsin inhibition was shown to be critical for tau cleavage and toxicity in
Drosophila tauopathy model (Khurana et al., 2010).
Heat Shock Factor 1 Regulation and Neurodegeneration
HSF1 is involved not only in heat shock response but also in development,
tumorigenesis, differentiation, and aging. HSF1-mediated transactivation of genes is not
only limited to molecular chaperones but also includes synaptic gene expression (Chen et
al., 2014, Wang et al., 2016). Thus, it is increasingly recognized that HSF1 protein is
important for synaptic integrity and memory consolidation process (Hooper et al., 2016).
Treatment of Hsp90 inhibitor, 17-AAG, led to increase synaptic proteins including PSD95 in primary neurons, dependent on HSF1 activation (Chen et al., 2014). In addition,
boosting HSF1 activity by CNS-permeable Hsp90 inhibitior, OS47720, atttenuated
cognitive deficits in the Tg2576 AD mouse model by upregulating expression of key
synaptic genes such as BDNF (Wang et al., 2016). Synaptic depolarization could induce
HSF1 activation in neurons, suggesting the relevance of HSF1 activation to synaptic
activity (Hooper et al., 2016). Non-canonical mechanism of neuroprotective HSF1
function was recently discovered by Verma et al., 2013. This study indicated that HSF1
activation was neuroprotective even in the circumstance irrelevant of proteotoxic stress.
They also demonstrated that the beneficial effect of HSF1 activation was not necessarily
mediated by trimerization-associated upregulation of downstream genes. This novel
trimerization-independent mechanism of HSF1 was proven to be effective in the
conditions of huntingtin-induced toxicity (Verma et al., 2013).
It should be noted that there have been increasing reports on the linkage between
intracellular level of HSF1 and neuronal survival/death (Jiang et al., 2013, Kondo et al.,
2013, Liu et al., 2011, Verma et al., 2013), suggesting that HSF1 loss may be a major
contributor to neurodegeneration. Jiang et al., 2013 identified an important role of HSF1
expression in the cerebellum of Ainfused AD rat model. Not only Hsp70 and Hsp40
expression but also steady-state level of HSF1 protein was significantly reduced in the
cerebellum of this AD model compared to that of control rats. They demonstrated that
enhancing HSF1 expression in the cerebellum of AD rat mitigated the loss of Purkinje
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cell bodies. Around the same time, Kondo et al., 2013 reported that HSF1 protein
expression influenced pathogenic androgen receptor accumulation in the mouse model of
spinal and bulbar muscular atrophy (SBMA). This mouse model overexpresses mutant
androgen receptor gene harboring the expansion of a CAG repeat. Enhancing HSF1
expression in the brain lesion attenuated pathogenic protein accumulation and neuronal
atrophy. On the other hand, HSF1 haploinsufficiency significantly promoted the
expansion of disease-affected areas in the brain of SBMA mouse model.
Structure and Function of HSF1
The family of heat shock factors including HSF1, HSF2, HSF3, and HSF4 is
evolutionarily highly conserved transcriptional factors responsible for the expression of
heat shock proteins. Major HSFs found in mammals are HSF1, HSF2, and HSF4 while
Drosophila, Caenorhabditis elegans, and yeast express only HSF1. In particular, HSF1 is
a master regulator of heat shock response (chapter 1.2.1) that governs the transcriptional
activation of chaperone genes during stress in eukaryotes and participates in a multitude
of physiological processes. Upon stress, inactive HSF1 mainly located in the cytoplasm
trimerizes and translocates into the nucleus where it binds to cis-acting heat shock
elements (HSEs, extended repeats of the sequence nGAAn) in the promoters of stress
responsive genes. The crucial function of HSF1 in regulating stress genes cannot be
compromised (compensated?) by other HSF family members. HSF1 depletion in mice
impaired thermotolerance by abolishing the induction of heat shock genes (McMillan et
al., 1998).
HSF1 protein is 529 amino acids with 5 structural domains (DNA binding
domain, two oligomerization domains, regulatory domain, trans-activating domain)
(Figure 1-1). First, oligomerization domain encompassing leucine zipper-like domain
(HR-A/B) located between DNA binding domain and regulatory domain and HR-C
located between regulatory domain and trans-activating domain regulates the
trimerization of HSF1 (Rabindran et al., 1993). Each unit (HR) is composed of an
amphiphilic helix and hydrophobic heptad repeats. Hydrophobic amino acids repeats
serve as a contact region for HSF1 each other. The interaction of HR-C with HR-A/B
hampers this intermolecular hydrophobic structure. DNA binding domain located in the
N-terminal ~100 amino acids is the most preserved region within the HSF family. Its
looped helix-turn-helix feature enhances the stability of DNA-bound HSF1 trimer by
protein-protein interactions without direct interaction with DNA. Each HSF1 monomer in
trimerization can bind to HSEs in the major groove of tthe target gene promoters. The
DNA-binding affinity of HSF1 tends to increase in trimeric HSF1 than monomeric HSF1.
HSF1 target genes usually have more than one HSEs in their promoters, allowing
simultaneous strong binding of HSF1 trimers. Trans-activation domain (TAD), the Cterminal 150 amino acids comprising two distinct domains TAD1 (401–420 a.a) and
TAD2 (431–529 a.a), regulates transcriptional activation of target genes. It has been
identified that acidic residues within TADs are involved in transcriptional initiation
whereas hydrophobic residues mediate translational elongation step (Brown et al., 1998).
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Figure 1-1. HSF1 Regulation by Post-Translational Modifications.
Oxidative posttranslational modification (Ox-PTM) of Cys residues (Cys36, Cys103, Cys
153, Cys173, Cys 378) can regulate HSF1 function. Phosphorylation of Ser230 and
Ser326 is positively correlated with HSF1 activity. Ser121, Ser 303, and Ser307 are
phosphorylation sites identified to suppress HSF1 activity. Lysine residues regulated by
SIRT1 and EP300 are represented.
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Without stress, regulatory domain (212-384 a.a) located between HR-A/B and HR-C
suppresses the HSF1 TAD (Green et al., 1995). The inhibitory effect of regulatory
domain on HSF1 transcriptional activation can be modulated by post-translational
modifications on multiple residues that reside in the regulatory domain.
Regulation of HSF1 Activation
HSF1 activation can be regulated by protein-protein interactions and posttranslational modifications. First, in the absence of stress, HSF1 activity is mainly
inhibited by its binding to heat shock proteins including Hsp70 and Hsp90. Therefore,
currently well-known HSF1 activators such as 17-AAG mostly act through inhibiting
Hsp90. More importantly, post-translational modification of HSF1 enables fine-tuning
HSF1 regulation in response to stress. Before this work, the consequence and mechanism
of HSF1 protein modification were exclusively revealed by studies in non-neuronal cells.
Phosphorylation. Twelve serine residues of HSF1 have been identified by mass
spectrometry (Ser(S)121, S230, S292, S303, S307, S314, S319, S326, S344, S363, S419,
and S444). Phosphorylation of Ser303 and Ser307 in the regulatory domain has been
clearly shown to suppress HSF1 activity (Kline et al., 1997, Neef et al., 2011), and these
two sites are considered as conserved motifs for GSK3 and ERK1. GSK3 and other
mitogen-activated protein kinases suppress HSF1 activity through phosphorylating
Ser303 residue (Kline et al., 1997). Phosphorylation of HSF1 on Ser121 residue in the
DNA binding domain by MAPK2 represses HSF1 activity by promoting its binding to
Hsp90 protein (Wang et al., 2006). In contrast, Ser230 and Ser326 present in the
regulatory domain are the phosphorylation sites positively associated with HSF1
activation. It is possible that CaMKII kinase activates HSF1 protein by regulating Ser230
(Holmberg et al., 2001).
Acetylation. In regards to regulation of HSF1 acetylation, K80 located in the
DNA binding domain is the most characterized site whose deacetylation showed a strong
positive correlation with HSF1 activity (Westerheide et al., 2009). Sirtuin 1 (SIRT1),
(discussed in detail in chapter 1.3.5), is an enzyme found to be responsible for HSF1
activation by deacetylating HSF1 K80 (Westerheide et al., 2009). This work also
demonstrated for the first time that K80 residue in HSF1 protein tends to be acetylated
upon both heat- and proteotoxic- stress. It is notable that downregulation of SIRT1 that
deacetylates HSF1 K80 site suppressed HSF1 binding to HSEs that exist in the promoters
of downstream target genes (Westerheide et al., 2009). HSF1 acetylation state can be
regulated not only by deacetylase SIRT1 but also by acetyltransferase EP300. In HeLa
cells, EP300 targeted K118-, K208-, and K298- residues in HSF1 protein (Raychaudhur
et al., 2013). In particular, acetylation of K118 by EP300 was found to occur in response
to heat shock stress (Raychaudhur et al., 2013). Knocking-down EP300 in HeLa cells
reduced the steady-state level of HSF1 protein, suggesting its new role on HSF1 protein
stability (Raychaudhur et al., 2013). In conclusion, HSF1 acetylation has two major
functions, regulating both HSF1 activation and HSF1 protein stability during stress.
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Ubiquitination. Studies to understand HSF1 ubiquitination are very limited until
now. FBXW7 ubiquitin ligase was identified to ubiquitilate HSF1 protein in cancer cells,
leading to its degradation (Kourtis et al., 2015). Loss of FBXW7 resulted in nuclear
HSF1 accumulation (Kourtis et al., 2015). HSF1 protein interacted with FBXW7 ligase
through Ser303/Ser307 (Kourtis et al., 2015). Chaperone-dependent E3 ubiquitin ligase
CHIP plays a crucial role in the ubiquitination of unfolded protein (Murata et al., 2001).
Despite its direct binding to HSF1 protein, it does not appear to be involved in HSF1
degradation through UPS. Rather, functional CHIP was required for HSF1 transcriptional
activation (Dai et al., 2003). Taken together, multiple post-translational modifications of
HSF1 have been studied using cancer cell lines in relation to its activity state including
acetylation and phosphorylation. However, regulation of HSF1 protein turnover remains
relatively unexplored, especially in neurons.
Heat Shock Proteins and Neurodegeneration
Chaperone proteins constitutively expressed inside cells, such as Hsp90, Hsp40,
and Hsc40, exert housekeeping functions. They participate in protein translation, folding
of newly synthesized protein and cellular translocation of protein (De Maio et al., 1999).
Co-localization of chaperones and toxic inclusion bodies may indicate irreversible
sequestration of substrate protein, and/or disability to correctly refold and degrade
misfolded protein. Cytosolic chaperones such as Hsp70 are often detected in extracellular
senile plaques, which might be associated with chaperone binding to lipid raft before A
secretion (Broquet et al., 2003). Manipulating chaperone proteins has been implicated as
a potential therapeutic strategy for treating neurodegenerative diseases.
In tau transgenic mouse models, several Hsp90 inhibitors significantly reduced
tau aggregates (Dickey et al., 2006, 2007, Luo et al., 2007). By studies from Dr.
Petrucelli group, Hsp90 inhibitors were found to selectively promote clearance of tau
phosphorylated at proline-directed Ser/Thr sites such as S202/T205, preferentially
through UPS system (Dickey et al., 2006). CHIP interaction with Hsp90 was required for
phosphorylated tau degradation, although HSF1 appeared not to play a role in CHIPHsp90 complex-mediated tau degradation (Dickey et al., 2007). Tortosa et al., 2009
reported that direct binding of Hsp90 to tau protein resulted in a conformational change
of tau and promoted GSK3-mediated tau phosphorylation and filament structure
formation. Tau phosphorylation is regulated by CDK5 as well as GSK3. p35 is a neuronal
specific co-activator of CDK5. Hsp90 formed a complex with p35 and P301L mutant tau
in JNPL3 tau transgenic mouse (Luo et al., 2007). In addition, Hsp90 inhibition reduced
CDK5 activity by downregulating p35 and promoted clearance of mutant tau
overexpressed (Luo et al., 2007).
Hsp90 inhibition induces Hsp70 expression. The Hsp70 family includes both
constitutively expressed Hsc70, stress-inducible Hsp70 in the cytoplasm and nucleus, and
endoplasmic reticulum localized Grp78. Inducible Hsp70 can be recruited into synapses
following hyperthermic stress (Moon et al., 2001). Exogenous expression of inducible
Hsp70 at synapses mimicked the effect of thermal preconditioning (Kelty et al., 2002).
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Overexpressing Hsp70 in -syn transgenic mice reduced triton insoluble -syn
aggregates and facilitated -syn degradation (Klucken et al., 2004, Donmez et al., 2012).
In a drosophila model of PD, although overexpressed Hsp70 protein did not alter -syn
inclusion, it was revealed to significantly prevent dopaminergic neuronal loss derived
from syn toxicity (Auluck et al., 2002). Furthermore, Hsp70 is likely to impede both
amyloid and tau pathology in AD. Virally mediated Hsp70 overexpression supressed
intracellular A accumulation by binding to APP (Magrane et al., 2004). Hsp70 could
suppress A oligomerization by recognizing exposed hydrophobic region in
Aoligomers to modify the conformation of oligomers (Lu et al., 2014). Enhanced
Hsp70 protein expression by geldanamycin, a Hsp90 inhibitor, increased both tau
solubility and binding affinity to microtubules, preventing tau aggregation (Dou et al.,
2003). Silencing Hsp70 resulted in the opposite outcome in vitro cellular model (Dou et
al., 2003). Later, it was further suppprted by in vivo study showing that both soluble and
insoluble tau protein were reduced in mice overexpressing Hsp70 compared to control
WT. Hsp70 and Hsp40 both prevented an intramolecular conformational change in a
mutant huntingtin fragment (Schaffar et al., 2004).
Small heat shock proteins are highly conserved chaperone proteins. These
proteins with low molecular mass of 12-43 kDa include Hsp27, αB-crystallin and Hsp20.
The common characteristic of small heat shock proteins is that they possess a conserved
-crystallin domain and form oligomers. Induction of their expression upon various
cellular stressors such as heat shock and ischemia is dependent on HSF1 transactivation.
Hsp27 has been identified to be upregulated in in vitro and in vivo models of
synucleinopathy and human DLB cases (Outeiro et al., 2006). Increased Hsp27 levels
were also observed in human AD brain as well (Björkdahl et al., 2008). Hsp27 had an
ability to bind to A to suppress its aggregation (Wilhelmus et al., 2006). In addition,
Hsp27 preferentially bound to hyperphosphorylated, pathological form of tau in human
AD samples (Shimura et al., 2004). Tau protein in NFTs appears to be positively
correlated with the levels of Hsp90, Hsp40, -crystallin, CHIP as well as Hsp27 in
human AD brain (Björkdahl et al., 2008). Triton soluble syn, not insoluble aggregates,
also showed a close correlation with these HSPs in the brains of DLB patients (Klucken
et al., 2006). In addition to its association with misfolded protein in neurodegeneration,
several studies pointed out its anti-apoptotic activity to suppress mitochondrial cell death
pathways by demonstrating that Hsp27 activated protective kinase Akt/PKB and
supreessed pro-apoptotic JNK pathway (Rane et al., 2003, Voss et al., 2007). Genetically
overexpressing Hsp27 in APP/PS1 of AD mouse model significantly attenuated various
symptoms including not only A accumulation but also memory dysfunction and
neuronal death (Tóth et al., 2013). There exists a controversy over the consequences of
Hsp27 expression in different HD mouse models. Transgenic overexpression of Hsp27
did not attenuate protein aggregation and disease progression in R2/6 of HD mouse
model (Zourlidou et al., 2007). In contrast, in HD rat models overexpressing mutated Htt
fragments via lentiviral delivery, Hsp27 not only rescued striatal dysfunction but also
increased solubility of aggregates, leading to decrease in the size of nuclear inclusions
(Perrin et al., 2007).
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HSF1 Activators
Direct HSF1 activator has not been identified. As Hsp90 is a major repressor
protein of HSF1 protein (Zou et al., 1998), many drugs that attempt to boost HSF1
activity are designed to inhibit Hsp90 function (Figure 1-2). Well-characterized Hsp90
inhibitors include geldanamycin and 17-AAG, both of which block the N-terminal ATP
binding pocket of ATPase activity. Their efficacy in ameliorating protein deposits and
neurotoxicity was demonstrated in both AD and PD mouse models (Chen et al., 2014,
Shen et al., 2005), while clinical success is limited mainly due to systemic toxicity and
BBB permeability. Celastrol, a Hsp90 inhibitor, acts through binding to C-terminal
domain of Hsp90, leading to inhibition of chaperone activity as well as promoting HSF1
activity. Celastrol treatment was shown to ameliorate amyloid beta pathology in Tg
PS1/APPsw of AD mouse model (Paris et al., 2010). However, its therapeutic potential
needs to be carefully determined because of the cytotoxicity involved with thiol reactivity
(Kalmar et al., 2009). In addition to Hsp90 inhibitors, by using a humanized yeast-based
high-throughput screen to search HSF1 activators, HSF1A was identified to enhance
HSF1 activity and chaperone expression, which led to decrease in protein aggregation
and toxicity in polyQ-expressing neuronal precursor cells (Neef et al., 2010). TRiC, a
central ATP-dependent chaperonin complex, is a negative regulator of HSF1 activation in
yeast and mammalian cells (Neef et al., 2014). HSF1A, a small molecule activator of
HSF1, is hypothesized to activate HSF1 by inhibiting the interaction of TRiC/CCT with
HSF1 (Neef et al., 2014).
Arimoclomol, an analog of bimoclomol, has an ability to induce HSPs expression
only under stress conditions (Kieran et al., 2004, Vigh et al., 1997). It circumvents any
side effects associated with non-specific targets of heat shock response by not inducing
stress response in the absence of stress (Vigh et al., 1997). In SOD1(G93A) of ALS
mouse model, arimoclomol treatment resulted in improvement of motor function and
motorneuron survival, significantly increasing lifespan (Kieran et al., 2004). Riluzole, a
FDA-approved drug for amyotrophic lateral sclerosis (ALS), was recently discovered to
stabilize HSF1 protein (Yang et al., 2008). Riluzole appears to attenuate HSF1
degradation via CMA sicne suppression of LAMP2A, a receptor for CMA substrates,
abolished the effect of riluzole to increase HSF1 protein expression (Yang et al., 2008).
By elevating HSF1 expression, riuzole treatment increased not only HSPs expression but
also glutamate trasporter 1 expression (Liu et al., 2011). The underlying mechanism of its
stabilizing effect on HSF1 protein remains to be further studied. Despite the benefical
effects of various HSF1 activators as demonstrated by numerous studies, in order to
develop HSF1-based therapy, it should be considered together that HSF1 has a powerful
multifaceted role in carcinogenesis (Dai et al., 2007).
Aging-related Changes in HSF1 and SIRT1 Activity
Sirtuins are a highly conserved family of protein deacetylase that influences
various cellular processes including stress resistance, apoptosis, inflammation, and
energy efficiency. Among seven homologues, SIRT1, a human homologue of SIR2, has
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Figure 1-2. HSF1 Activation by an Hsp90 Inhibitor.
An Hsp90 inhibitor releases of HSF1 from Hsp90, leading to transactivation of Hsp
genes. Post-translational modification of HSF1 protein such as acetylation and
ubiquitination likely contributes to nuclear HSF1 degradation.
Data Source: Kim E, Wang B, Sastry N, Masliah E, Nelson PT, Cai H et al. (2016)
NEDD4-mediated HSF1 degradation underlies α-synucleinopathy. Hum Mol Genet
25:211-222
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been mostly characterized in mammals. SIRT1 has been highly implicated to promote
longevity in a variety of organisms and emerged as a neuroprotective molecule in
neurological diseases. There is a great body of evidence supporting the crucial roles of
SIRT1 in both A and tau pathology. While SIRT1 overexpression ameliorated A
production and plaque formation, SIRT1 deletion deteriorated amyloid plaque formation
(Postina et al., 2004). Later, it was identified that acetylation of tau mediated by p300
acetyltransferase inhibited its degradation whereas SIRT1-mediated deacetylation of tau
protein promoted ubiqutination and degradation of tau in neurons (Min et al., 2010). A
linkage between SIRT1 decrease and disease progression was further supported by
postmortem investigations. The levels of SIRT1 expression were inversely correlated
with insoluble PHFs tau and Ain human AD brain (Julien et al., 2009). Of note, SIRT1
activity is tightly linked to HSF1 activation as described above in Chapter 1.3.2.
Attenuation of stress response is a characterstic of senescence. Ben-Zvi et al., 2009
demonstrated in Caenorhabditis elegans that proteostasis network became compromised
during aging. The steady-state level of HSF1 protein was downregulated in senescent WI38 fibroblasts when compared to young fibroblasts (Westerheide et al., 2009). Aging
considerably reduced the levels of Hsp70 mRNA induction following heat stress in various
rat tissues including brain (Blake et al., 1991, Blake et al., 1990, Pardue et al., 1992). While
36 months- and 6 months-old rat brain were comparable in the levels of HSF1 protein
expression, the aged brain clearly showed defects in the HSF1 ability to form trimerization
(Akerfelt et al., 2010). Stress response is intimately linked to proper degradation of
misfolded proteins via degradation pathways, and proteasome and autophagic activity
decline with aging. Collectively, the critical role of HSF1 in proteinopathies ties in well
with the aging-associated feature of neurodegenerat.
Hypothesis, Rationale, and Specific Aims
Hypothesis
We hypothesize that dysregulation of HSF1 protein represents an important
mechanism underlying neurodegeneration (Figure 1-3).
Rationale
Neurodegenerative diseases are characterized by neuronal loss in the brain and the
current classification of the diseases is largely based on disease-targeted region of the
brain. The common characteristic of the affected areas in neurodegeneration is
aggregation of misfolded proteins, for which they can be defined as proteinopathies in the
brain. It has been widely accepted that a build-up of misfolded protein can be triggered
and exacerbated by disrupted proteostasis. Proteostasis is mainly achieved by protein
quality control including chaperones and degradation system. Much of the disease-
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Figure 1-3. Aberrant HSF1 Degradation as a Common and Important Key
Molecular Mechanism Underlying Neurodegeneration.
(Left) The general concept of molecular chaperones and UPS activated in normal healthy
cells upon stress. (Right) Proposed model based on our novel findings.
Data Source: Kim E, Wang B, Sastry N, Masliah E, Nelson PT, Cai H et al. (2016)
NEDD4-mediated HSF1 degradation underlies α-synucleinopathy. Hum Mol Genet
25:211-222
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associated mutations implicated in neurodegeneration are directly or indirectly related
with this defense system. Aging is a most critical factor accelerating the pathogenesis of
neurodegenerative diseases, and the function of nearly all protein quality control systems
appears to be compromised in aged neurons. In the lifetime, neurons can experience
different kinds of stresses that include proteotoxic stress from misfolded protein. During
stress response, chaperone proteins are upregulated to clear misfolded protein via UPS
and/or autophagy. In contrast to healthy cells, aged cells and unhealthy cells under
pathological conditions appear to lose their ability to fully activate a stress response,
possibly leading to inclusion bodies formation in the brain.
Therefore, it is essential to understand the underlying mechanism that can explain
the attenuated stress response in degenerating neurons and how failure of stress response
contributes to the toxicity of protein aggregates. Most of all, HSF1, a master regulator of
heat shock response, has been reported to be intrinsically related with other protein
quality control systems (Dou et al., 2003, haggerty et al., 2011, Pierce et al., 2013). Since
recent evidence strongly suggests important neuroprotective function of HSF1 in the
brain, it is imperative to investigate how HSF1 protein is regulated in neurons undergoing
chronic proteotoxic stress in AD and PD brain. This work may reveal the central role of
HSF1 protein in neurodegeneration in cooperation with other cellular protective
pathways.
Specific Aims


Aim 1. To investigate whether and how HSF1 is dysregulated in synucleinopathy.



Aim 2. To investigate whether and how UPR activation affects HSF1 dysregulation
and vice versa in tauopathy.



Aim 3. To investigate if HSF1 haplodeficiency affects hippocampal-dependent
memory function.
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CHAPTER 2.

METHODS

Animal and Human Studies
Strains and Genotyping
HSF1+/- mice (from Jackson laboratory, they came on the B6 background) were
crossed once to C57BL/6J and maintained via intercrossing the F1 HSF1+/- mice.
rTg4510 mice were produced by crossing Tau responder line with CaMKII-tTA
transactivator line. PS19 mice were obtained on a C57BL/6J genetic background from
Jackson laboratory. WT α-syn transgenic mice were generated by Dr Cai’s laboratory
using the same strategy as described previously (Lin et al., 2009). Mouse tail was cut by a
sterilized scissor. PCR was performed by using KAPA2G Fast PCR kit and GoTaq Flexi
DNA Polymerase (Promega). HSF1 mice were genotyped by PCR with the following
primer sequences: HSF1 mutant forward CGG TCG CTA CCA TTA CCA GT; HSF1
mutant reverse CCA AGG AGA TGT AGT GAG GTC TG; HSF1 wild type forward
CTC CAT CTC CAG CCT ACA GC; HSF1 wild type reverse AGA GTG CTG CTG
GAC AGA GG. PS19 mice were genotyped by PCR with the following primer
sequences: Transgene reverse GGT ATT AGC CTA TGG GGG ACA C; Transgene
forward GGC ATC TCA GCA ATG TCT CC; internal positive control forward CAA
ATG TTG CTT GTC TGG TG; internal positive control reverse GTC AGT CGA GTG
CAC AGT TT.
Intraperitoneal Injection and Intra Substantial Nigra Viral Microinjection
Mice were anesthetized by intraperitoneal injection of 10% chlor- al hydrate 3.5
ml/kg, and were stereotaxically fixed and injected with AAV2 or AAV5-CBA-α-syn
virus into the right substantia nigra of brains (5.25 × 10 13 vg/ml, 1.5 μl at 0.5 μl/min
speed, anter- ior fontanelle 4.4 mm, sagittal suture (right) 1.3 mm, 8.5 mm under the
skull). Viruses were generously provided by The Michael J. Fox Foundation for
Parkinson’s disease Research. Samples of different brain regions from single or double
-syn transgenic mice were used for biochemical examination. To induce UPR
activation, five month-old C57BL6 mice were intraperitoneally administered with
thapsigargin (2 mg/kg) dissolved in PBS with 10% DMSO.
Histology
Mouse cardiac perfusion was performed by a steady flow injection of phosphate
buffered saline (PBS) and 4% paraformaldehyde (PFA) for fixation. A double-staining
protocol was used to compare Tau46 immunoreactivity to thioflavin S staining of plaques
in floating sections from HSF+/- and WT. Monoclonal Tau46 antibody recognizes
endogenous levels of total tau protein. The immunostaining procedure was performed
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before thioflavin S staining. We followed the procedure for thioflavin S staining
described in Ly et al., 2011. For p-PERK (Thr980) and p-Tau (Ser202/Thr205) staining,
images were captured under a confocal microscope (Olympus America, Center Valley,
PA, USA). Mouse brain slices co-stained with Thioflavin S and Tau46 were observed by
Olympus fluorescent microscope and a confocal microscope.
Synaptosomal Membrane Preparation and Sarkosyl Insolubility Assay
Mouse hippocampus was homogenated into sucrose-HEPES buffer (4 mM
HEPES pH 7.4, 3 mM Sucrose, 2 mM EGTA, containing protease and phosphatase
inhibitors). Centrifuge the homogenate at 1,000 g for 10 min at 4 oC to remove the
pelleted nuclear fraction. The resulting supernatant from further centrifugation at 15,000
g for 15 min at 4 oC yielded the crude synaptosomal pellet. Resuspend the resulting pellet
into sucrose-HEPES buffer. The resulting supernatant from further centrifugation at
15,000 g for 15 min at 4 oC was discarded to remove contaminants. The pellet was then
lysed in 4 mM pH 7.4 HEPES and incubated at 4 oC for 30 min. The resulting pellet from
further centrifugation at 25,000 g for 30 min contained synaptosomal membrane fraction.
Sarkosyl-insoluble tau protein from mouse hippocampus was biochemically isolated as
described in de Calignon et al., 2012.
Behavior Tests
Behaviors of ~13 month-old WT (HSF1+/+), ~13 month-old HSF1+/-, and ~25
month-old HSF1+/- were examined by a set of behavior tests as below.
Open field test. Mouse was placed in an open field chamber (47 × 37 × 20 cm,
Accuscan Instruments) and allowed to freely explore for 10 min. Experiments were
performed between 10 AM to 4 PM. Sixteen infrared beams could automatically measure
total locomoter activity of mouse by beam-breaks. EthoVision XT and video tracking
software were used to track the mouse movement. The size of center region was about 25
% of the total field. Measurements in the test included distance travelled, center duration,
center frequency, center latency, total activity, movement (and rest) time, and etc.
Cross maze. Mouse was placed from one entry of a cross-shaped maze made of
opaque plastic walls (arm/wall sizes: 50 L × 10 W × 30 H, cm), and allowed to freely
explore four different arms during the 5 min test. The pattern of arm choices was
automatically recorded by Maze software. The spontaneous alternation rate was
calculated by dividing the number of alternations by the number of total arm entries. One
alternation was counted when mouse made successive entries into each of the four arms.
The number of total entries into arms was also analyzed.
Elevated plus maze. To assess anxiety-related behaviors, mouse was placed in
the entry of open arm and allowed to freely explore for 5 min session. The elevated plus
maze apparatus consists of two facing open arms, two facing closed arms and a center
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zone (arm/wall sizes: 50 L × 10 W × 30 H, cm; Runway height from floor: 55 cm). This
test was to measure the time spent in open or close arms. The total number of arm entries
was also measured as a reference of general activity.
Fear conditioning test. Fear conditioning test was performed as previously
described (Chen et al., 2014; Kittelberger et al., 2012). Mouse was placed in a steel
chamber equipped with an overhead camera to monitor mouse movement (30 L x 30 W x
25 H, cm, Coulbourn Instruments LLC). Freezing percentage was determined by
FreezeFrame software (Coulbourn Instruments LLC). Fear acquisition was performed on
Day 1. The first three minutes was to record baseline activity and then mouse was
subjected to a 2 s footshock (0.7 mA). After another one minute recording, mouse was
given the second similar shock stimulus followed by additional one minute recording.
Contextual fear retention was tested on the next day (24 hr later). Three minutes
recording was performed for the fear retention test; minute 1 (m1): 0–60 s; minute 2
(m2): 60–120 s, minute 3 (m3): 120–180 s.
Morris water maze test. To examine spatial learning and memory, mouse was
subjected to the Morris water maze test (Morris et al., 1984). Mouse was placed in a
circular pool of water that was made opaque with non-toxic paint (114 cm in diameter),
and allowed to freely swim. This test prompted mouse to escape from water onto a
hidden platform (10 cm in diameter) under the surface of water (0.5 cm in depth). There
were four trials per day in the cued and hidden platform sessions. A visible sign for
mouse to locate the platform was placed above the platform only during the cued sessions
(day 1-4). For each trial in the hidden sessions, mouse started from different quadrants.
Measurements of the test included the latency for mouse to locate the platform and total
distance travelled. For a probe trial at the end of hidden sessions, mouse was allowed to
swim for 1 minute in the pool where the platform was removed.
Human Specimens
Tissue specimens of Non-AD and AD patients were obtained from the Human
Brain and Spinal Fluid Resource Center, which is sponsored by NIHDS/NIMH, National
Multiple Sclerosis Society, Department of Veterans Affairs. Cases derived from shortpostmortem interval (PMI) autopsies from the University of Kentucky AD Center (UKADC) cohort (Schmitt et al., 2012). Premortem clinical evaluations and pathological
assessments were as described previously (Nelson et al., 2010). Frontal cortical sections
correspond to Brodmann Area 9. Tissue used for the biochemical analyses were snapfrozen during the autopsy in liquid nitrogen and then stored at -80 oC. The inclusion/
exclusion criteria that were applied: PMI <4 hrs; no evidence of frontotemporal dementia
(clinically) or frontotemporal lobar degeneration (pathologically); no cancer in the brain
parenchyma; and no large infarctions in the brain, or microinfarcts found within 3 cm of
the brain tissue samples. The neuropathological features were assessed using standard
neuropathological procedures as described in detail elsewhere (Nelson et al., 2009, 2010).
Human snap-frozen inferior parietal (Brodmann Area 39) samples used for the study
were provided by the Biobank at Uni- versity of Kentucky Alzheimer’s Disease Center
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(Schmitt, et al., 2012). Neuropathologic diagnoses were as described previously and
inferior parietal lobe tissue was used because when that is affected one can be confident
of the ‘diffuse/neocortical’ subtype of DLB (Nelson et al., 2009-2). Whole brain lysates
or tissue lysates from distinct brain areas of mice were used for western blotting.
Biochemical Studies
Cell Cultures and Generation of Stable Cell Lines
SH-SY5Y cells were cultured in Dulbecco’s modified Eagles’ me- dium (DMEM)
supplemented with nutrient mixture F-12 and 10% fetal bovine serum (FBS). Human
embryonic kidney (HEK) 293 cells were grown in DMEM plus 10% FBS. Cells were
trans- fected with plasmids using Lipofectamine 2000 (Invitrogen) and harvested 2 days
after transfection. N2a cells were cultured in a 1:1 mixture of DMEM and Opti-MEM
containing 10% fetal bovine serum (FBS). Cells were transfected with plasmids using
Lipofectamine 2000 (Invitrogen). For generation of stably transfected cell lines (N2aTauRDΔK280), G418 at 1mg/ml was included in the culture medium. Primary cortical and
hippocampal neurons were prepared from E17 rat embryos and maintained in neurobasal
medium supplemented with 0.8 mm l-glutamine and B27. Primary neurons cultured for
10-18 days in vitro (DIV) were used for the study.
Reagents and Plasmids
Plasmid constructs used in transient transfection include full length tau (WT,
R406W) and repeated domain tau constructs (TauRD WT, TauRD P301L, TauRD ΔK280);
pcDNA-SIRT1 WT; pcDNA-HSF1 WT, S303A and HSF1 Δ156–226; pcDNA-HSP70a5
(BiP/GRP78). HSF1 WT and HSF1 S303A were generously given by Dr. Dennis Thiele
at Duke University. HSF1 Δ156–226 (trimerization mutant) was cloned by using a
method of site-directed mutagenesis (Agilent Technologies). Tunicamycin, thapsigargin,
salubrinal, resveratrol, piceid, celastrol, rapamycin, and riluzole were all purchased from
Sigma. siRNA oligomers for CHOP and BiP were purchased from Sigma and SIRT1
siRNA from Cell Signaling. RSV, MG132, cycloheximide, NAM, sirtinol were all from
Sigma-Aldrich. Chloroquine diphosphate sulfate was from MP Biomedicals. Plasmid
constructs used in transient transfection include EGFP-C1-WT α-syn, pEGFP-C1- A53T
mutant α-syn and empty vector pEGFP-C1; pcDNA-SIRT1 WT and mutant SIRT1
H355A; pRC-CMV-NEDD4 WT and NEDD4 C866S; HSF1 WT; HA-Ub. HSF1 LPKY
deletion mutant, HSF1 K80Q and K80R were cloned by using a method of site-directed
mutagenesis (Agilent Technologies)
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Protein Analysis by Western Blots
Tissues and cells were lysed using RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM
EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl)
containing protease inhibitor (leupeptin, pepstatin A, phenylmethylsulfonyl fluoride
(PMSF), aproptinin). The resulting lysates were subjected to western blots. Both
monoclonal antibody (Santa Cruz, E-4) and polyclonal antibody (Cell signaling, 4356)
were used to study HSF1 protein expression. Both antibodies detected ~ 82 kDa HSF1
but showed different banding patterns. SIRT1 (Millipore) and p-PERK/p-eIF2/
eIF2BiP/CHOP/Tau (Tau46) (these six from Cell signaling) were also used in the
study. Tau (Tau46) Mouse monoclonal antibody detects all six isoforms of tau based on
the amino acid sequence. For phosphorylated tau, two specific antibodies of AT8
(MN1020) and AT100 (MN1060) were purchased from Thermofisherscientific. Western
quantification was based on the intensity of interested signal using densitometry and
ImageJ software program.
In Vivo Ubiquitination Assay and Cycloheximide Chase Assay
Transfected cells were lysed in buffer (2% SDS, 150 mM NaCl, 10 mM Tris–
HCl, pH 8.0) with 2 mM sodium orthovanadate, 50 mM sodium fluoride and protease
inhibitors. The resulting lysates were boiled for 10 min and sheared by sonication. For
immunoprecipitation, the HSF1 containing protein complexes were pull-down by antiHSF1 antibody, washed and eluted from beads via boiling and subjected to immunoblot
using anti- ubiquitin antibody (Enzo Life Sciences). Western quantification was based on
the intensity of interested signal using densitom- etry and ImageJ software program. In
SH-SY5Y cells, 100 μM (Sigma) cycloheximide was added for the indicated times in the
presence or absence of MG132 24∼48 h after transfection of empty or A53T vector with
or with- out SIRT1 WT constructs. Cell lysates were then prepared for fur- ther analysis.
RNA Analysis (PCR and qRT-PCR)
Total RNA in HEK293 and SH-SY5Y cells was prepared by following the Trizol
RNA Isolation Protocol (Life Technology). By using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems), single-stranded cDNA was synthesized from
total RNA. Mixtures of cDNA, SYBR Green MasterMix (5 Prime, Inc.), and primers
were analyzed by Real-time PCR system (Invitrogen) to measure RNA levels.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Assay
Cells in a 24 well-plate were incubated with 10 µl of the 12 mM MTT stock
solution in a total 100 µl fresh culture medium for 2~3 hrs at 37 °C. Reaction was stopped
by incubation with 100 µl of the SDS-HCl solution for 2.5 hrs. Absorbance at 570 nm
was detected by Beckman Coulter DTX 880 multimode detector
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Immunofluorescence Analysis
SH-SY5Y cells and mouse brain tissues were fixed in 4% paraformaldehyde,
human brain was fixed in 10% formalin, all followed by sectioning and then blocking and
incubation of primary antibody overnight and then AlexaFluor-conjugated secondary
anti- body. Fluores- cence image were captured by confocal and fluorescence microscopy
(Olympus).
Statistical Analysis
All statistical analysis was performed by Student’s t-test for two groups’
comparison and one-way ANOVA with a Tukey test for multiple comparisons.
Quantitative data in all graphs were presented by means ± SEM (standard error of mean).
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CHAPTER 3.

THE ROLE OF HSF1 PROTEIN REGULATION IN
SYNUCLEINOPATHY*
Introduction

Synucleinopathies are a major class of neurodegenerative dis-eases, including
Parkinson’s disease (PD) and diffuse lewy body (DLB). These pathologic conditions are
defined by the presence of pathological α-synuclein aggregates known as Lewy bodies.
Disruption of protein quality control, interconnected cellular strategies of the ubiquitin
proteasome system (UPS) and molecular chaperones, has been postulated to be involved
in the patho-genesis of neurodegeneration underlying proteinopathies (Chen et al., 2011).
Molecular chaperones composed of a set of heat shock proteins (HSPs) are considered a
first line of defense against misfolded and aberrantly accumulated proteins like αsynuclein aggregates that trigger the pathologic cascade and eventually lead to deficits in
the overall protein clearance. For unknown mechanism, several cell types including
neurons appear to be poorly adapted for chronic proteotoxic stress (Morimoto et al.,
2008). Since the induction of HSPs is primarily determined by the activation of heat
shock transcription factor 1 (HSF1), HSF1 has been regarded as an attractive target for
treating neurodegenerative diseases (Neef et al., 2011). Multiple post-translational
modifications of HSF1 have been studied in relation to its activity state, including
acetylation, sumoylation and phosphorylation (Lindquist et al., 1986, Cotto et al., 1998,
Zou et al., 1998, Shi et al., 1998, Morimoto et al., 1998). However, regulation of HSF1
turnover remains relatively unexplored, especially in neurons. It should be noted that
there have been increasing reports on linking the intracellular level of HSF1 with
neuronal survival/death (Jiang et al., 2013, Kondo et al., 2013, Liu et al., 2011, Verma et
al., 2014), suggesting that HSF1 loss can be a major contributor to neurodegeneration. In
this work, we discovered the ‘neural precursor cell ex- pressed, developmentally downregulated 4 (NEDD4-1, NEDD4 herein)’ (Yang et al., 2010, Donovan et al., 2013) likely
being the E3 ligase of HSF1 in neurons under proteotoxic stress conditions. We speculate
that aberrant HSF1 degradation is a common and important key molecular mechanism
underlying neurodegeneration. Moreover, HSF1 deacetylation can attenuate this process
via stabilizing HSF1 protein.

*

Reprinted with permission. Kim E, Wang B, Sastry N, Masliah E, Nelson PT, Cai H et
al. (2016) NEDD4-mediated HSF1 degradation underlies α-synucleinopathy. Hum Mol
Genet 25:211-222
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Results
Overexpressed α-syn Protein Promotes Ubiquitination and Degradation of HSF1
Protein via UPS
To determine whether α-synuclein (α-syn, herein after) aggregation altered HSF1
expression levels, we transiently transfected SH-SY5Y neuroblastoma and HEK293 cells
with GFP-tagged wild-type (WT) α-syn (GFP-α-syn WT) or GFP-tagged A53T mutant αsyn (GFP-α-syn A53T). In both cell lines, A53T α-syn overexpression 48 h post
transfection caused more dramatic re- duction (>70% loss) in HSF1 protein expression
than WT α-syn (Figure 3-1A, C), without decreasing the mRNA levels of hsf1 gene
(Figure 3-1B). A53T mutant form of α-syn is known to aggregate more rapidly than WT
form. We could detect both Triton X-soluble and detergent-insoluble α-syn aggregates in
α-syn transfected SH-SY5Y cells (Figure 3-1D). Insoluble WT α-syn expression was
increased by transfection of double concentration of WT α-syn (WT 2 μg) (Figure 3-1D).
This higher WT α-syn aggregation resulted in ∼50% loss of HSF1 protein (Figure 3-1A,
C). In contrast to A53T α-syn which resulted in HSF1 loss in both nuclear and
cytoplasmic compartments, WT α-syn only caused reduced HSF1 in the nucleus (Figure
3-1C).
We next assessed HSF1 protein stability by treating transfected cells with
cyclohexamide (CHX). While HSF1 protein was stable in SH-SY5Y cells transfected
with empty vector, it was greatly reduced in cells overexpressing A53T over time
(Figure 3-1E), which was largely rescued by proteasome inhibitor MG132 but not by
chloroquine (CQ, a lysosomal inhibitor). Of note, we noticed upshifted HSF1 bands in
both control and A53T- trasnfected cells when blocking proteasomal degradation with
MG132 (Figure 3-1E; denoted by *). This slower mobility-shifted band may be due to
hyperphosphorylated HSF1 which correlated with hyperactivated HSF1 following heat
shock and proteasomal stress (Holmberg et al., 2001).
α-Syn-induced HSF1 Degradation is Mediated by the E3 ligase NEDD4
UPS degradation is mediated by ubiquitin E3 ligase conjugating ubiquitin
molecules to a lysine residue of substrate protein. Previously, we discovered that E3
ubiquitin-protein ligase NEDD4 expression was upregulated in the brain samples of PD
patients (Kwak et al., 2012). The LPKY-motif in the endoplasmic reticulum localized
transcription factor Spt23p was previously shown to interact with yeast Rsp5
(mammalian homolog NEDD4) (Schcherbik et al., 2004). We found the same motif in the
DNA-binding domain of HSF1 (57–60 amino acid sequence). Therefore, we reasoned
that NEDD4 may be involved in HSF1 protein degradation. Indeed, we observed
significant enhancement of NEDD4 expression and in particular nuclear NEDD4 during
α-syn-induced HSF1 degradation (Figure 3-2A, B, and C). NEDD4 appeared to undergo
active shuttling between nuclear and cytoplasmic compartments upon overexpressing
A53T as compared with its perinuclear distribution in control cells, as detected by both
subcellular fractionation assay and confocal microscopy (Figure 3-2B, C).

30

Figure 3-1. α-Syn Aggregation Causes HSF1 Degradation via UPS.
(A) Immunoblot assay showing the expression levels of HSF1. SH-SY5Y cells were
transiently transfected with different concentrations of WT α-syn or A53T α-syn
plasmids. Quantification of the western blot images was done by densitometry (right, n =
3, ***P < 0.001, means ± SD). (B) Quantitative measurement of HSF1 mRNA levels
normalized by GAPDH transcripts in transfected SH-SY5Y cells by qRT-PCR (n = 3,
***P < 0.001; *P < 0.05, data represent means ± SD). (C) Subcellular fractionation assay
to separate nuclear and cytoplasmic HSF1. Cells were transfected with different amounts
of α-syn (WT or A53T) constructs. (D) Following Triton X-100 fractionation, both
insoluble and soluble α-syn were detected by using α-syn antibody instead of GFP
antibody in transfected SH-SY5Y cells (arrow represents monomeric α-syn of 18 kDa
size. *tetramer of α-syn). (E) Proteosomal HSF1 degradation induced by A53T α-syn.
SH-SY5Y cells were treated with 50 μM CHX for various time points with or without
pretreatment of 25 μM MG132, 48 h after transfection. MG132 but not CQ (50 μM)
blocked HSF1 degradation (right panel). Control was transfected with empty vector (A–
E). (F) HSF1 ubiquitination in A53T α-syn transfected cells. Co-immunoprecipitation of
ubiquitin (Ub) with HSF1 using antibody against HSF1 was performed with protein
extracts of A53T-transfected SH-SY5Y cells with or without MG132 treatment (left
panel). GFP-α-syn A53T was transiently co-transfected with various amounts of HAtagged ubiquitin (HA-Ub) into SH-SY5Y cells (right panel). The HSF1-complexes
immunoprecipitated from lysates with anti-HSF1 antibody were then subjected to
immunoblot using an antibody against ubiquitin. HSF1 abundance showed an inverse
relationship to the level of ubiquitination.
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Figure 3-2. NEDD4 Promotes Ubiquitination and Proteasomal Degradation of
HSF1 in Neuroblastoma cells Overexpressing A53T α-syn.
(A) Elevated NEDD4 and decreased HSF1 protein levels by A53T α-syn overexpression
in SH-SY5Y and HEK293 cells. Cells were transfected with empty GFP vector (control),
α-syn WT or α-syn A53T. (B) Intracellular NEDD4 protein expression (red) in SH-SY5Y
cells with or without A53T α-syn was visualized by immunocytochemistry. DAPI (blue)
was used for nuclear staining. The merged images are presented in the bottom. Scale bar:
10 μm. (C) Subcellular fractionation assay to separate nuclear and cytoplasmic NEDD4.
SH-SY5Y cells were transfected with α-syn (WT or A53T). Lamin B1, a nuclear
envelope marker, was shown to indicate nuclear fraction. (D and E) NEDD4 WT
overexpression in SH-SY5Y cells transfected with A53T α-syn further decreases HSF1,
inducible Hsp70 and α-syn levels and increases expression of pro-apoptotic factor Bax.
SH-SY5Y cells were transfected with A53T α-syn, along with NEDD4 WT, NEDD4
C866S or NEDD4 siRNA. Quantification of HSF1 protein expression was normalized to
β-actin (n = 3, **P < 0.01, means ± SD). (F) NEDD4 WT overexpression facilitates
ubiquitination of HSF1 in A53T-transfected cells (left panel). The interaction between
NEDD4 and HSF1 (right panel). Three days after transfection of GFP-A53T or empty
GFP vector alone or together with HA-Ub in SH-SY5Y cells, endogenously expressed
HSF1 proteins were pull-down in whole-cell lysates, followed by immunoblot using antiUb and anti-NEDD4 antibody (right panel).
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To investigate NEDD4-mediated HSF1 degradation, we overexpressed WT
NEDD4 (NEDD4 WT) in A53T-transfected SH-SY5Ycells. It should be noted that
A53T-transfected SH-SY5Ycells overexpressing NEDD4 WT showed ∼50% reduction of
HSF1 along with decreased inducible Hsp70 (iHsp70) whose ex- pression is regulated by
HSF1 activation (Figure 3-2D). On the contrary, overexpression of catalytically
defective NEDD4 mutant (NEDD4 C866S) as well as NEDD4 siRNA failed to reduce
HSF1 protein (Figure 3-2E), indicating that the ubiquitin ligase activity of NEDD4 was
required for the loss of HSF1 protein. We then detected enhanced mono-and
polyubiquitination of HSF1 in SH- SY5Y cells overexpressing NEDD4 WT (Figure
3-2F) which was further facilitated by expression of exogenous HA-Ub in both control
and A53T-transfected cells (Figure 3-2F). Moreover, the strength of NEDD4– HSF1
interaction appeared to be positively correlated with the degree of HSF1
polyubiquitination and its degradation (Figure 3-2F). Taken together, we could conclude
that despite the reduction in α-syn (Figure 3-2D, E), degradation of HSF1 was further
promoted by NEDD4 overexpression in A53T-transfected SH- SY5Y cells.
Loss of HSF1 Protein Induced by α-synucleinopathy in vivo
We determined the protein expression profiles of HSF1 and NEDD4 in the brain
of PITX3-IRES2-tTA/tetO-syn inducible double transgenic mouse expressing WT αsyn under the PITX3 promoter predominantly expressed in midbrain dopaminergic
neurons. TetO-α-syn single transgenic mouse was used as a control to compare with
double transgenic mice overexpressing α-syn mostly in the midbrain area. By
immunostaining, we confirmed somatic accumulation of α-syn in tyrosine hydroxylase
(TH)-positive dopaminergic neurons in midbrain substantia nigra of 12-month-old double
transgenic mouse (Figure 3-3A). This abnormal accumulation of α-syn in cell bodies was
recently identified to be correlated with progression of neurodegeneration in α-syn
transgenic mice (Lin et al., 2009). Our results showed that the most reduction in HSF1
protein was detected in the midbrain samples of double transgenic mice where α-syn was
highly overexpressed, accompanied by strongly elevated NEDD4 in those compared with
control (Figure 3-3B, C). However, the other three regions, hippocampus, cortex and
cerebellum, did not show significant changes (Figure 3-3B). Interestingly, we observed
two bands of HSF1 proteins only in mouse tissues; the upper band is higher than its
predicted molecular weight of 82 kDa which might be due to by post-translational events
such as phosphorylation (Figure 3-3B). Although NEDD4 expressed primarily in the
perinucleus of neurons in the age-matched control mice, we observed that NEDD4 was
enormously induced in the soma of cells where α- syn accumulated in the brain slices of
α-syn transgenic mice by immunohistochemistry (Figure 3-3C). While Lewy body in PD
is primarily found in the midbrain substantia nigra and locus ceruleus, DLB is also
categorized as α-synucleinopathy present in the subcortical and
The review of literature provides an overview of the evolving significance of
heart rate variability (HRV) as a surrogate measure of autonomic function. HRV is
defined and a synthesis of its measurement methods and parameters given. Research
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Figure 3-3. Reciprocal NEDD4 and HSF1 Levels in Mouse and Human Tissue of
α-synucleinopathy.
(A) Somatic α-syn overexpression (red) in the substantia nigra of α-syn double transgenic
mice. Green and yellow indicate TH-positive cells and those with somatic α-syn
aggregation, respectively. Scale bar: 10 μm. (B) (Top panels) Western blot analysis of the
midbrain tissue of TetO-α-syn single and α-syn double transgenic mice (12 months of
age). Quantification of HSF1/NEDD4 protein expression (***P < 0.001, *P < 0.05,
means ± SD). (Bottom panels) Western blots on four different areas of the brain (i.e.
hippocampus, midbrain, cerebral cortex and cerebellum) with equal loading of total
proteins. S, single transgenic mice (control); D, double transgenics (α-syn Tg). The red
arrow indicates the predicted molecular weight of HSF1 (82 kDa). (C) Confocal
microscopy of the substantia nigra from single and double α-syn transgenic mice. Top
panels: HSF1 (red); α-syn (green). Bottom panels: NEDD4 (red); α-syn (yellow). Scale
bar: 10 μm (top panels) and 2 μm (bottom panels). (D) Western blot analysis of the
inferior parietal lobes of human patient specimens with and without diffuse Lewy body
disease (left panel). Immunohistochemistry of HSF1 (red) and α-syn (green) (right panel).
Scale bar: 10 μm.
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exploring cardiac and non-cardiac physical conditions, and psychosocial factors,
cortical (frontotemporal) regions of the brain. We observed a striking decrease in HSF1
and NEDD4 upregulation within the inferior parietal lobes of human patients with DLB
where Lewy body deposits were located (Figure 3-3D). Cleaved-caspase 3 as a marker of
apoptosis was highly expressed in the individuals with reduced HSF1 (Figure 3-3D, left
panel). Immunostaining of HSF1 showed a punctate pattern which colocalized with
aggregated α-syn, likely indicating stress granules (Figure 3-3D, right panel).
Since reciprocal expression levels of NEDD4 and HSF1 were found in mouse and
human tissue of α-synucleinopathy, we then sought in vivo evidence of α-syn-induced
HSF1 degradation. Six-month-old C57BL/6 mice were injected with AAV2 or AAV5CBA-α-syn in the right substantia nigra and AAV-CBA-eGFP virus in the left side as
control (Figure 3-4A). Remarkably, 3 weeks later, drastic HSF1 degradation was
detected only in the right side of substantia nigra overexpressing α-syn (Figure 3-4B, C),
ac- companied by markedly increased NEDD4 which appeared to co-localize with α-syn
around perinucleus (Figure 3-4D). In addition to immunohistochemistry, 5–6 weeks after
injection, the cortex and midbrain samples of two AAV2-CBA-α-syn injected mice and
one AAV5-CBA-α-syn injected mouse were subjected to the western blot, which clearly
demonstrated HSF1 degradation and NEDD4 elevation in the targeted midbrain area of
AAV2-α- syn injected mice (Figure 3-4E).
The Role of Acetylation Status in NEDD4-mediated HSF1 Degradation via Interplay
with Ubiquitination
In addition to ubiquitination, acetylation of HSF1 was remarkably elevated by
A53T α-syn aggregation in SH-SY5Y cells (Figure 3-5A). Resveratrol (RSV) has been
shown to protect neurons against α-syn toxicity in a SIRT1-dependent mechanism
(Donmez et al., 2012). We investigated the effect of RSV on HSF1 levels as well as on its
acetylation state. We found that 5 μM of RSV was able to decrease α-syn expression and
increase HSF1 protein levels while decreasing HSF1 acetylation levels (Figure 3-5A).
Most strikingly, NEDD4 overexpression resulted in reduced HSF1, correlating with
highly acetylated HSF1. The RSV’s effect on reducing HSF1 acetylation appeared to be
dependent on its action on SIRT1 activation. Since co-transfection of A53T α-syn with
SIRT1 siRNA completely abolished its beneficial effect (Figure 3-5B). The tight
regulation of HSF1 expression levels by SIRT1 was further confirmed by adding sirtuin
inhibitors, sirtinol or nicotinamide (NAM), or co-transfection with a dominant-negative
(DN) SIRT1 H355A defective in catalytic function (Figure 3-5E). Furthermore, SIRT1
WT overexpression prevented HSF1 degradation in A53T- transfected cells without
altering HSF1 mRNA levels (Figure 3-5C). SIRT1 overexpression led to reduced
interaction between HSF1 and NEDD4 as well as decreased polyubiquitination of HSF1
(Figure 3-5D). Taken together, HSF1 acetylation status appeared to be positively
correlated with its ubiquitination but negatively with HSF1 protein stability under both
basal and A53T-stressed conditions.
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Figure 3-4. HSF1 Degradation Induced by AAV-α-syn Viruses in Mouse
Substantia Nigra.
Young adult C57BL/6 mice were injected with AAV-α-syn or control eGFP viruses each
side of SNc (n = 4). (A–D) HSF1, NEDD4 and α-syn levels were detected by
immunohistochemistry. (A) Representative image of both sides of substantia nigra (SNc)
is shown, each receiving AAV2-eGFP control (left side) or AAV2-α-syn viruses (right
side). White dotted boxes indicate the SNc regions. Scale bar: 500 μm. (B) Coronal brain
slices were stained for HSF1 (red) and α-syn (green); immunopositive signals are
indicated by white arrows within the SNc regions. White circle shows that the α-synpositive region is devoid of red HSF1 signal. Scale bar: 1 mm. (C and D) The same brain
slice from panel B was examined under confocal microscope, showing immunopositive
signals of HSF1, NEDD4 and α-syn with higher magnification. Scale bars: 10 μm (C) and
5 μm (D). (E) Western blot analysis of the cortex (unaffected area used as control) and
midbrain where SNc is located of two AAV2-α-syn injected mice and one AAV5-α-syn
injected mouse. L, left side injected with AAV-GFP virus; R, right side subjected to
AAV-α-syn virus injection.
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Figure 3-5. HSF1 Acetylation/Deacetylation and Ubiquitination.
(A and B) SH-SY5Y cells were co-transfected with NEDD4 WT plasmid or SIRT1
siRNA (B) for 48 h with or without co-treatment of RSV. After transfection and RSV
treatment, cell lysates were analyzed by acetylation assay using immunoprecipitation and
western blot. (C and D) Effects of SIRT1 WT overexpression on HSF1 deacetylation,
ubiquitination and NEDD4 interaction with HSF1. (E) Effect of 5 mm NAM on HSF1
and α-syn protein expression levels. Quantification of HSF1 protein levels normalized to
β-actin in cells treated with 10 μM sirtinol and 5 mm NAM, and overexpressing SIRT1
H355A (n = 3, *P < 0.05, ***P < 0.001, means ± SD). (F) Cells overexpressing A53T
with or without SIRT1 WT were co-transfected with HSF1 WT or HSF1 K80Q or HSF1
K80R. The resulting cell lysates were subjected to in vivo ubiquitination assay.
Endogenous HSF1 was pulled down by HSF1 antibody and HSF1-complex was
subjected to immunoblot with anti-NEDD4 and anti-ubiquitin antibodies. In vivo
ubiquitination assay in control cells without A53T mutation (right panel).
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K80 is the lysine site located in the DNA-binding domain of HSF1 where its
deacetylation was found to increase DNA-binding activity on the promoters of HSP
genes (Westerheide et al., 2009). Therefore, it has been indirectly implicated as the major
target by SIRT1 whose activation causes a delay in the attenuation of heat shock response
(HSR). Given the positive role of SIRT1 in stabilizing HSF1 protein, we sought to
determine if K80 is also responsible for the underlying mechanism. We replaced K80
with either glutamine (K80Q) to mimic acetylation or arginine (K80R) as nonacetylatable mutation. Results from the CHX experiment indicated that the extent of
HSF1 degradation was minimized in A53T-transfected SH-SY5Y cells overexpressing
K80R as compared with K80Q (data not shown). Accordingly, while HSF1 K80R was
completely resistant to ubiquitination, HSF1 K80Q was highly mono- and polyubiquitinated than HSF1 WT was (Figure 3-5F). This tendency of HSF1 ubiquitination
upon K80 residue was preserved in SIRT1-overexpressing A53T-transfected cells
(Figure 3-5F). Similarly, under basal condition without A53T stress, only K80Q
mutation caused HSF1 polyubiquitination (Figure 3-5F).
Downregulation of NEDD4 or Overexpression of HSF1 or RSV Provides
Neuroprotection against α-synucleinopathy
In support of the previously identified neuroprotective role of HSF1, we
confirmed that overexpression of HSF1 (or HSF1 S303A, a constitutively activated form
of HSF1) greatly reduced α-syn toxicity as measured by α-syn aggregation and reactive
oxygen species (ROS) levels in A53T-trasnfected cells (Figure 3-6A, B). Furthermore,
downregulation of NEDD4 (or C866S NEDD4) resulted in similarly outcomes
(Figure 3-6A, B, C, and D). On the contrary, NEDD4 overexpression led to increased
caspase-3 activation, despite decreased α-syn aggregation from NEDD4 overexpression
in cells overexpressing A53T α-syn (Figure 3-6A, B, C, and D). This is consistent with
the results from western blot suggesting that the pro-apoptotic Bax was rather increased
although α-syn accumulation was reduced upon NEDD4 overexpression (Figure 3-2E).
Finally, RSV was proven to be protective as reported previously (Figure 3-6A, B, C, and
D).
Summary
Here we have provided compelling and novel in vitro and in vivo evidence that
proteotoxic stresses, as exemplified by α-synucleinopathy, induce rapid and sustained
HSF1 protein degradation mediated by the E3 ligase NEDD4 through UPS. First, we
discover aberrant HSF1 degradation by aggregated α-synuclein (or α-synuclein-induced
proteotoxic stress) in transfected neuroblastoma cells.
We show here that both WT and A53T mutant α-syn caused HSF1 protein
degradation to varying degrees: while A53T α-syn-induced HSF1 lost in both cytosolic
and nuclear compartments, WT α-syn overexpression appeared to only induce loss of
nuclear HSF1. Whether nuclear HSF1 is more vulnerable to proteotoxic stress remains
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Figure 3-6. Effects of Down-regulated NEDD4 or Overexpressed HSF1 or RSV on
α-syn Toxicity.
(A and B) ROS production was determined by DHE staining (red) for different groups of
cells. Green indicates GFP-A53T α-syn expression. A53T α-syn transfected SH-SY5Y
cells were co-transfected with NEDD4 WT, NEDD4 C866S or HSF1 S303A
(constitutively activated) or treated with RSV 50 μM. Scale bar: 30 μm (A). Graph
indicates the percentage of fluorescence intensity per 100 cells (B). (C and D) Apoptotic
cells identified by positive cleaved caspse-3 staining (red) with DAPI nuclear staining
(blue). A53T α-syn transfected SH-SY5Y cells were co-transfected with NEDD4 WT or
NEDD4 siRNA, or treated with RSV 20 μM. Quantification of cleaved-caspase 3 stained
nucleus for each group, represented as percentage on the graph (D). Scale bar: 30 μm (B
and D graphs, n = 4, *P < 0.05, **P < 0.01, ***P < 0.001, means ± SD). (E and F) The
effect of WT and different mutant forms of HSF1 overexpression on A53T α-syn-induced
apoptosis was determined by positive cleaved caspase-3 signals. (E) Representative
image of GFP-A53T α-syn (top panels) and cleaved caspase-3 staining (bottom panels) in
transfected groups of cells. Red: cleaved caspase-3, Blue: DAPI, Green: GFP-A53T αsyn. Scale bar: 2 mm. (F) Quantitative analysis of expression of A53T α-syn and cleavedcaspase 3, showing significant difference in the number of GFP and activated-caspase 3
positive cells compared with the single (A53T) transfection group (n = 3, *P < 0.05, **P
< 0.01, ***P < 0.001, means ± SD). Around 100 cells were counted for each transfected
group. (G) Western blot representing change in expression levels of inducible Hsp70,
GFP-α-syn, and Bax as a result of overexpression of WT HSF1 and S303A/K80R/ K80Q
mutant forms of HSF1, as well as RSV 20 µM treatment in A53T α-syn-transfected cells.
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unclear. Importantly, HSF1 dysregulation via α-synuclein was confirmed by in vivo
assessment of mouse and in situ studies of human specimens with α-synucleinopathy. We
demonstrate that elevated NEDD4 is implicated as the responsible ubiquitin E3 ligase for
HSF1 degradation through UPS. Furthermore, pharmacologically induced SIRT1mediated deacetylation can attenuate aberrant NEDD4-mediated HSF1 degradation.
Indeed, we define the acetylation status of the Lys 80 residue located in the DNA-binding
domain of HSF1 as a critical factor in modulating HSF1 protein stability in addition to its
previously identified role in the transcriptional activity. We demonstrate that the same
Lys 80 acetylation state directly correlates with the ubiquitination levels and the stability
of HSF1. The underlying mechanism is unclear. Our study has demonstrated the potential
significance of SIRT1-mediated deacetylation in HSF1 stability, adding to the growing
body of evidence of sirtuins in the regulation of proteostasis (Sampalo-Marques et al.,
2015). Fully delineating the underlying mechanism of SIRT1-mediated proteostasis will
facilitate development of this promising strategy.
Together with the finding that preserving HSF1 can alleviate α-synuclein toxicity,
this study strongly suggests that aberrant HSF1 degradation is a key neurodegenerative
mechanism underlying α-synucleinopathy. This work suggests that aberrant HSF1 protein
degradation may represent a common and important key molecular mechanism
underlying neurodegeneration.
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CHAPTER 4.

THE ROLE OF HSF1 PROTEIN REGULATION IN
TAUOPATHY
Introduction

Neurofibrillary tangles (NFTs) of phosphorylated tau aggregates and senile
plaques of amyloid beta (A) are the pathological hallmarks of Alzheimer’s disease (AD)
patients. A toxicity has been known to contribute to synaptic loss and cognitive
impairment, the mechanism of which appears to be tau-dependent (Mukaetova-Ladinska
et al., 2000, Nelson et al., 2010, Nijholt et al., 2012). However, NFTs, not amyloid
plaques, have been identified to correlate best with the severity of dementia (Arriagada et
al., 1992, Mocanu et al., 2008). NFTs exist primarily inside the cell, and have been
associated with cellular stress responses (Butler et al., 1986, de Calignon et al., 2012,
Shipton et al., 2011). Such response systems include unfolded protein response (UPR)
initiated in the endoplasmic reticulum (ER) and cytoplasmic heat shock response initiated
by heat shock factor 1 (HSF1) activation. Both pathways involve transcriptional
activation of the stress-response genes. A key feature of heat shock response is to induce
a set of molecular chaperone proteins such as Hsp70 whose function is to correct protein
folding in response to numerous cellular stresses. Likewise, UPR is initially triggered as
an adaptive response to disturbances in ER homeostasis. In this sense, HSP70 a5
(BiP/GRP78), a major ER chaperone Hsp70, has been found to attenuate ER stress by
activating sensors of transmembrane ER stress, such as PERK, via direct binding
(Bertolotti et al., 2000). However, sustained chronic UPR activation as a result of
unresolved ER stress can eventually trigger cell death by inducing pro-apoptotic proteins
such as C/EBP homologous protein (CHOP) primarily through the PERK/eIF2α/ATF4
pathway (Gorbatyuk et al., 2013, Roberson et al., 2007, Spillantini et al., 1997). A close
correlation between ER stress markers and NFTs has been consistently reported in human
tauopathies such as AD and frontotemporal dementia (de Calignon et al., 2012, Mori et
al., 1992, Rapoport et al., 2002). Ho et al., 2012 has shown that ER stress can cause tau
hyperphosphorylation in primary cultured neurons (Guettouche et al., 2005). However, it
is unknown whether and how ER stress causes tau phosphorylation, and vice versa.
While these two stress systems (i.e. heat shock response, UPR) have been originally
considered to be individually triggered by distinct stressors, recent studies have begun to
highlight the importance of heat shock responses in relieving ER stress in non-neuronal
cells (Dou et al., 2003, haggerty et al., 2011, Hou et al., 2014, Schmitt et al.,2012).
Nevertheless, how ER stress affects HSF1-mediated stress response is poorly understood,
particularly in the contexts of neurons and tauopathy.
We recently identified aberrant HSF1 degradation via ubiquitin proteasome
system as an important mechanism underlying synucleinopathy (Homma et al., 2007).
Synucleinopathy has been suggested to be pathogenetically linked with tauopathy as
reflected by their frequent co-occurrence in neurodegenerative diseases and the
synergistic interaction of tau and synuclein (Drexler et al., 2009, Giasson et al., 2003, Lee
et al., 2010). Tauopathy is characterized by a build-up of tau aggregates, and thus the
notion that HSF1 could also be degraded by tau aggregation stands as an intriguing
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possibility. In an attempt to understand human AD tau pathology, experimental murine
tauopathy has been generated by introducing mutations in the human tau gene causing
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) such as
P301L and ΔK280 (Hunsberger et al., 2015, Min et al., 2010). Presence of UPR
activation in the tau transgenic mouse models has not been clearly defined. Spatara et al.,
2010 reported that PS19 mice harboring human tau P301S variant did not show any signs
of UPR activation (Ramsden et al., 2005), whereas Abisambra et al., 2013 provided some
evidence of UPR activation in rTg4510 mice overexpressing human tau carrying the
P301L mutation (Abosambra et al., 2013). Relative to the P301L missense mutation, the
Tau ΔK280 mutation has been known to aggregate faster than any other single missense
mutation (Resende et al., 2008). Tau ΔK280 mutation has never been discussed in terms
of its involvement of UPR activation. Here, we examined the impact of ER stressinduced UPR activation on HSF1 protein and vice versa in promoting aberrant tau
pathology in AD. We investigated how UPR effector proteins such as CHOP and HSP70
a5 (BiP/GRP78) regulate HSF1 to potentiate a vicious cycle active in the cellular
tauopathy model (N2a-TauRDΔK280). Our work highlights that HSF1 loss may
constitute a mechanistic connection between ER stress and tau hyperphosphorylation,
especially in stress-vulnerable neuronal populations such as the hippocampus or aged
brain.
Results
Loss of HSF1 Protein Is an Early Event That Precedes NFTs Formation in AD,
Which Is Further Exacerbated in the Presence of PERK (or UPR) Activation in the
Brains of Mouse and Human Tauopathy
To determine whether expression of HSF1 protein and UPR marker proteins was
altered in the mouse tauopathy models, we looked at the brains of PS19 (tau P301S)
mouse and rTg(tauP301L)4510 mouse overexpressing P301S and P301L mutant tau,
respectively. It was previously reported that synaptic function was impaired in 3 monthold PS19 mouse before NFTs that consist of insoluble hyperphosphorylated tau
developed at 6 months of age (Yoshiyama et al., 2007). In the brain of 4 month-old PS19
mouse, we found that overexpressed mutant tau was not hyperphosphorylated at
Ser202/Thr205 (p-Tau, detected using the AT8 antibody) (Figure 4-1A, P < 0.01, n = 5).
Upon activation of the UPR signal, PERK is phosphorylated at Thr980 (p-PERK). While
PERK was not activated, about 30 % of HSF1 protein was lost in the brain of PS19
mouse before tau hyperphosphorylation at a presumably later stage (Figure 4-1A, P <
0.05, n = 5). Insoluble tau filaments were previously detected in 4 month-old rTg4510
mouse (Ramsden et al., 2005). We observed that overexpressed mutant tau was highly
phosphorylated in the brain of rTg4510 mouse, about 2.7-fold increase in the levels of pTau normalized to total tau protein (Tau46), at 4 months of the same age with PS19
mouse above (Figure 4-1B, P < 0.001, n = 5). Activated PERK causes phosphorylation
on Ser51 of the subunit of eukaryotic translation initiation factor 2 (p-eIF2). Together

48

Figure 4-1. HSF1 Protein Loss and Chronic UPR Activation in the Brain of
rTg(tauP301L)4510, and Minor Loss of HSF1 Protein in the Brain of PS19
(tauP301S).
(A) Expression levels of HSF1, p-PERK (Thr980), total Tau (Tau46), and p-Tau
(Ser202/Thr205) in PS19 (tauP301S) and WT at 4 months of age were determined by
western blot. *: ~ 68 kDa tau isoform. (B) HSF1 loss and UPR activation in the brains of
rTg(tauP301L)4510 at 4 months of age. Expression levels of HSF1, p-PERK (Thr980), peIF2Ser51), total Tau (Tau46) and p-Tau (Ser202/Thr205) in rTg4510 brain were
determined by western blot (A vertical line highlights UPR marker proteins, herein after).
Arrow indicates the band of p-eIF2 at 38 kDa, its original size. Tau46 antibody is
expected to detect total Tau at 50-80 kDa. Control mice used are (from left to right)
single transgenic (Tg) CaMKII-tTA, single Tg TRE-tau, non-Tg, non-Tg, and single Tg
TRE-tau. Quantification of p-PERK, HSF1 (normalized to -actin) and p-Tau
(Ser202/Thr205) protein (normalized to total Tau protein (Tau46)) in the whole brain
samples of PS19 (A), rTg4510 (B) and their control (means ± SEM, *P <0.05, **P
<0.01, ***P <0.001, comparing to control, n= 5 (A), n = 10 (B)).

49

with p-PERK and p-eIF2 elevation, increased expression of pro-apoptotic protein
CHOP suggested later apoptotic stage of UPR chronically activated in the brain of
rTg4510 mouse (Figure 4-1B, p-PERK, P < 0.001, n = 5) (Wang et al., 1996, Zinszner et
al., 1998). We detected a dramatic loss of HSF1 expression levels, about 60 % reduction
in rTg4510 mouse brain in which PERK (or UPR) was activated (Figure 4-1B, P < 0.01,
n = 5).
The Braak NFT staging system is used to classify the anatomical distribution of
AD-type NFTs according to stages (I/II, entorhinal-; III/IV, limbic-; and V/VI,
neocortical-stage) (Braak et al., 1991). To identify the sequential relationship of
molecular events in AD brain, we determined the expression levels of HSF1 protein and
UPR marker proteins in the frontal lobes of 19 human postmortem brain specimen,
spanning different Braak NFT stages. Distribution of HSF1 protein mostly in the
cytoplasm suggested its inactivation in aged human brain since HSF1 is a nuclear
transcriptional factor likely to be located in the nucleus when it is activated
(Figure 4-2A). More importantly, we did observe gradually decreased expression of
HSF1 protein that occurred even before formation of NFTs composed of
hyperphosphorylated tau (Figure 4-2A, B, and C). While PERK activates eIF2 during
UPR activation upon ER stress, other serine kinases such as general control
nonderepressible 2 (GCN2) can also phosphorylate eIF2 in response to other stresses
including amino acid deprivation. In incipient AD stages III/IV (before the frontal cortex
starts to form NFTs), we observed about 58 % reduction in HSF1 protein and slightly
increased p-eIF2 without PERK activation (Figure 4-2B, C). UPR was activated in
later stage V patients diagnosed with early onset AD (EAD) and AD patients in stage VI,
as reflected by marked hyperactivation of PERK and eIF2 (Figure 4-2B, C). About
59% of total HSF1 protein in Stages III/IV was further lost in stages V/VI when UPR was
activated. It should be noted that stage V patients diagnosed with EAD demonstrated
significantly greater p-PERK and less HSF1 protein expression when compared to AD
patients in stage V (Figure 4-2B). Taken together, these results identify that a dramatic
loss of HSF1 protein is an early and progressive event that may precede PERK activation
and NFTs formation in murine tauopathy and human AD.
Haploinsufficiency of HSF1 Leads to Chronic PERK Activation and Causes
Aberrantly Phosphorylated Tau Aggregation and Its Mislocalization in the Aged
Mouse Hippocampus
Next, we investigated if HSF1 protein loss altered the expression levels of UPR
marker proteins and tau phosphorylation in the brain of HSF1 haploinsufficient mouse
(HSF1+/-). Phosphorylation at Thr212/Ser214 (p-Tau, detected using the AT100
antibody) was not detected in the hippocampus of 2 month-old HSF1+/- and WT
(Figure 4-3A). However, PERK and CHOP protein were highly activated in the
hippocampus of 9 month-old HSF1+/-, although p-eIF2 was not elevated (Figure 4-3B,
p-PERK (Thr980), P < 0.001; CHOP, P < 0.01, comparing to 9 month-old WT
hippocampus, n =6). By immunohistochemistry, we found that activated PERK (p-
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Figure 4-2. HSF1 Loss and UPR Activation in the Frontal Cortex of Human
Brain at Different Stages of Alzheimer's Disease Progression (Braak Staging).
(A) Tau aggregation and a dramatic loss of HSF1 protein in human AD brain of Braak
stage VI. Phosphorylated tau (p-Tau (Ser202/Thr205), detected by AT8 antibody), red)
and HSF1 protein expression (green) in four different Braak stages (Braak stage I, III, IV,
VI) were visualized by immunostaining. Scale bar: 1 mm. (B) Protein lysates from frontal
cortex of human brain at various Braak I-VI stages were subjected to western blot. EAD:
early-onset Alzheimer's disease (AD). (C) Quantitative measurement of protein levels of
p-PERK (blue), p-eIF2green) and HSF1 (red) normalized to -actin in human brain
samples of distinct Braak stages (Braak stages I/II (Clinically silent cases); III/IV
(Incipient AD); V/VI (Fully developed AD)). Error bars represent standard error of mean
(SEM). Means indicated in the graph. The effect of left on right on each arrow is
discussed in the following figures indicated

51

WT

A

HSF1+/- 2 months

WT

B
HSF1

p-Tau (Ser202/Thr205)

HSF1 +/- 9 months
HSF1 +/-

*
p- PERK
(Thr980)

p-Tau (Thr212/Ser214)
CHOP

72 kDa
Tau46

C

56 kDa

p-eIF2 a
(Ser51)

b-actin

eIF2 a

CHOP

b-actin

Red : p-Tau (Ser202/Thr205) Green : p-PERK (Thr980)

Merged

D

RIPA solulble
WT

HSF1 +/- 9 months
95 kDa

#
*

HSF1+/-HSF1 +/-

p-Tau (Ser202/Thr205)

p-Tau (Thr212/Ser214)

Tau46

WT

56 kDa

b-actin

Sarkosyl insoluble
WT
14 months

HSF1+/14 months

HSF1+/25 months

WT

130 kDa

**

95 kDa

*

p-Tau (Ser202/Thr205)

Figure 4-3. Chronic UPR Activation and Aberrantly Hyperphosphorylated Tau
Aggregation in the Hippocampus of Aged HSF1 Haploinsufficient Mouse.
(A,B,D) Western blot assays to examine protein expression levels of total tau (Tau46), pTau (at Ser202/Thr205 and Thr212/Ser214) and UPR marker proteins (p-PERK, p-eIF2,
eIF2, and CHOP) in the hippocampus of WT and HSF1+/- at 2 months of age (A) and
hippocampus of WT and HSF1+/- at 9 months of age (B, D). (B) Increased p-PERK
(Thr980) and CHOP protein expression in the hippocampus of 9 month-old HSF1
heterozygous knock-out mice (HSF1+/-). Relative protein levels of CHOP and p-PERK
(Thr980) normalized to -actin in WT and HSF1 +/- at ~9 months of age are presented in
the graph (right, means ± SEM, **P < 0.01, ***P < 0.001, n = 6). Western blots of
RIPA-soluble tau (A and D) and sarkosyl-insoluble tau aggregates (D) in the mouse
hippocampus. #: 72~80 kDa tau isoform, *: ~ 68 kDa tau isoform, arrow head indicates
~64 kDa tau isoform, **: ~110 kDa high molecular weight tau isoform. (C)
Representative confocal images of immunohistochemistry on the hippocampus of HSF1
+/- and WT at 13 months of age. co-immunostaining of p-Tau (Ser202/Thr205, red), pPERK (Thr980) (green), and DAPI (blue) in HSF1+/-. Arrow heads indicate colocalization of p-PERK and p-Tau (Ser202/Thr205) in the middle panels, enlarged
images of top panels. Five repeated experiments performed. Scale bars : 5 µM.
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PERK, green) largely co- localized with of increased p-Tau (Ser202/Thr205, red) in the
hippocampus of HSF1+/- at 13 months of age (Figure 4-3C). Of note, a dramatic
upregulation of p-Tau (detected by both AT8 and AT100 antibodies) was strongly found
in the hippocampus of 9 month-old HSF1+/- by western blot (Figure 4-3D, p-Tau
(Ser202/Thr205), P < 0.01; p-Tau (Thr212/Ser214), P < 0.05, n = 6). These changes were
not detectable in the whole brain lysates of 9 month-old HSF1 +/- (data not shown). Tau
isolated from PHFs in human AD brain has been reported to contain ~60-, ~64-, and ~68kDa tau isoforms (Liu et al., 1993). In our study, the strongest immunoreactive band for
phosphorylated tau protein in HSF1+/- was detected at ~68 kDa (Figure 4-3D). In the
aged HSF1+/- hippocampus, there were two major p-Tau bands at ~64- and ~68- kDa
with a minor band at ~72 kDa, similar to the pattern observed in human tauopathy brain
(Spillantini et al., 1997) (Figure 4-3D). These are considered to be low molecular weight
tau, ranging in 50-68 kDa on SDS-PAGE (Binder et al., 1985, Butler et al., 1986).
Sarkosyl insolubility assay is used to isolate tau paired helical filaments found in NFTs
from AD brain (Greenberg et al., 1990). In the sarkosyl-insoluble fraction from the
hippocampus of aged HSF1+/-, we found high molecular weight tau isoform,
approximately 110 kDa tau, in addition to a major band of ~68 kDa (Georgieff et al.,
1991) (Figure 4-3D). Paired helical filaments from AD brain bind to Thioflavin S (SantaMaria et al., 2006). We did not observe any significant change in the expression levels of
p-Tau and CHOP in the hippocampus of HSF1+/- at 2- and 6-months of age
(Figure 4-4). By double staining using thioflavin S and Tau antibody (Tau46), aggregates
of hyperphosphorylated tau were found in the hippocampus of 13 month-old HSF1+/-,
not in WT control (Figure 4-5). Diffuse plaques that showed strong positive signals for
thioflavin S consisted of tau proteins (Figure 4-5). Thioflavin S staining also revealed
globose-type NFTs and diffuse plaques in the cortical areas adjacent to the hippocampus
(Figure 4-5).
Although tau protein is most abundant in axons, abnormal modifications of tau
such as hyperphosphorylation can lead to redistribution of tau from neuronal processes to
the soma where it likely forms toxic oligomers or aggregates (Tashiro et al., 1997).
Hyperphosphorylation of tau has been identified to mislocalize tau to dendritic spines in
neurons in AD models (Hoover et al., 2010). By subcellular fractionation and isolation of
cytoplasm and synaptosome, both cytoplasmic- and synaptic- tau were found to increase
in the hippocampus of 13 month-old HSF1+/- compared to WT control hippocampus
(Figure 4-6A). We found increase in the average of the relative expression of p-Tau
(Ser202/Thr205) in the cytoplasm and synaptosomal membrane of the hippocampus of 6
month-old HSF1+/- compared to that of 6 month-old WT (Figure 4-6A, cytoplasmic pTau (Ser202/Thr205), P < 0.05). Clearly, expression levels of p-Tau (Ser202/Thr205)
were significantly upregulated in the both cytoplasm and synaptosomal membrane of the
hippocampus of 14- and 25- month-old HSF1+/- compared to that of 14 month-old WT
(Figure 4-6B).

53

Figure 4-4. A Graph Shows Quantitative Measurement of the Relative Tau
Phosphorylation Normalized to Total Tau (Tau46) in the Hippocampus of WT and
HSF1+/- at 2, 6, and 9 Months of Age.
Two distinct p-Tau antibodies (AT8 (Ser202/Thr205) and AT100 (Thr212/Ser214)) used.
(means ± SEM, *P < 0.05, **P < 0.01, n = 3 (2 months), n = 4 (6 months) n = 6 (9
months)).

Figure 4-5. Double Staining with Thioflavin S (green, a) and Tau46 Antibody
(red, b) in the Hippocampus of 13 Month-old HSF1 +/-.
Merged images of the hippocampus of HSF1+/- (c). Globose-type NFTs and diffuse
plaques containing tau aggregates in the cortical areas adjacent to the hippocampus of
HSF1+/- (d-i). Scale bar : 1 mm.
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Figure 4-6. Abnormal Mislocalization of Hyperphosphorylated Tau in the Hippocampus of HSF1 Haploinsufficient Mouse.
(A) PSD-95 highly enriched in the synaptosomal membrane fraction of 13 month-old mouse hippocampus. Tau46 antibody was used
to detect total tau protein in the crude cytoplasm and synaptosomal membrane fraction. (B and C) Increased expression of p-Tau
(Ser202/Thr205) in the cytoplasm and synaptosomal membrane fraction from the hippocampus of HSF1+/-. Graphs indicate
quantification of p-Tau (Ser202/Thr205) protein levels normalized to -actin (cytoplasm) and PSD-95 (synaptosomal membrane) in
the hippocampus of WT and HSF1+/- at different ages as indicated (means ± SEM, *P < 0.05, **P < 0.01, n = 4 (B), n = 3 (C)).
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eIF2-CHOP Activation Is Involved in Autophagy-Lysosomal HSF1 Protein
Degradation during Chemically Induced ER Stress in Neurons
We observed that loss of HSF1 protein was more severe in the brains of rTg4510
and Braak stages V/VI subjects where PERK was activated when compared to that of
age-matched PS19 and stages III/IV subjects that did not show PERK activation,
respectively (Figure 4-1, 4-2). Thus, we asked if UPR activation was involved in HSF1
protein loss in rat primary cultured neurons. Thapsigargin triggers ER stress by inhibiting
Ca2+-transporting, ATPase mediated uptake of calcium ions into the sarcoplasmic
reticulum. It is well documented that rapamycin, an inhibitor of mTOR (mammalian
target of rapamycin), represses ER stress in various cell types (Kato et al., 2012).
Rapamycin seemed to act as a reliable inhibitor of CHOP expression both in the presence
and absence of thapsigargin in primary cortical neurons (Figure 4-7A, B, and C, , P <
0.001, n = 3-4). We demonstrated that thapsigargin triggered pro-apoptotic UPR
activation that was attenuated by co-treatment of rapamycin (Figure 4-7A, B, and C). Of
note, thapsigargin treatment led to ~54 % reduction in the HSF1 protein levels in primary
neurons (P < 0.05, n = 4), which was nearly blocked by rapamycin (Figure 4-7B, C).
CHOP activation could be further enhanced by salubrinal treatment which inhibits
activity of protein phosphatase 1 and prolongs eIF2 phosphorylation. In contrast to
rapamycin, salubrinal treatment further aggravated HSF1 loss from thapsigargin-induced
ER stress in primary neurons (Figure 4-7B, ). Autophagy activity, as determined by
LC3 II accumulation, was increased in thapsigargin-treated neurons (Figure 4-7B, ).
Treatment of autophagy-lysosomal blocker, NH4Cl, inhibited thapsigargin-induced HSF1
loss, revealing HSF1 protein degradation through autophagy-lysosomal system (Figure
4-7B, a solid line indicated). Although direct HSF1 activator has not been identified, we
previously reported that resveratrol could prevent HSF1 degradation from proteotoxic
stress (Kim et al., 2016). In the current study, resveratrol attenuated thapsigargin-induced
HSF1 protein degradation in primary neurons (Figure 4-7B, a dashed line indicated).
Tunicamycin is another chemical UPR inducer that causes protein unfolding by blocking
the glycoprotein synthesis pathway. Tunicamycin also reduced HSF1 protein expression
in primary cultured cortical and hippocampal neurons (Figure 4-7D). We then sought in
vivo evidence of thapsigargin-induced HSF1 degradation. Five month-old C57BL/6 mice
were injected with thapsigargin (i.p. 2 mg/kg) or PBS containing 10% DMSO.
Remarkably, 6 hrs later, drastic HSF1 degradation, about 50% reduction in HSF1 protein
expression, was detected in the mouse brain injected with thapsigargin (Figure 4-7E, P <
0.01, n = 5).
Overexpressed Pro-Aggregation Mutant TauRD ΔK280 Leads to HSF1 Degradation
Which Is Further Exacerbated by eIF2-CHOP Activation
Loss of HSF1 protein began to occur even in the absence of PERK activation in
Braak stage III/IV and PS19 mouse (Figure 4-1, 4-2). There is a possibility that
proteotoxic stress from pathogenic tau affected HSF1 expression (Kim et al., 2016). To
determine if overexpressed mutant tau caused HSF1 protein loss and eIF2-CHOP
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Figure 4-7. Autophagy-Lysosomal HSF1 Protein Degradation Mediated by
eIF2-CHOP Activation during Chemically Induced Acute ER Stress in Neurons.
(A) Reduced pro-apoptotic CHOP activation by rapamycin treatment during thapsigargin
(TG)-induced ER stress. Primary cortical neurons were pre-treated with rapamycin (0.4
𝜇M, for indicated duration time) followed by TG incubation (1 𝜇M, the last 6 hr).
Cleaved-caspase 3 as apoptotic marker. (B) The combination treatments of ER stressinducer (TG, 1 M), ER stress-inhibitor (rapamycin, 0.5 M), p-eIF2 activator
(salubrinal, 20 M), lysosomal blocker (NH4Cl, 5 mM) and resveratrol (5 M) for 6 hr in
primary cortical neurons to study the relationship between HSF1 protein and eIF2CHOP activation. LC3 II increase by TG and NH4 Cl (LC3 I and II (autophagy markers)).
 : thapsigargin,  : co-treatment of thapsigargin and rapamycin,  : co-treatment of
thapsigargin and salubrinal, A solid and a dashed line indicate the treatments of NH4Cl
and resveratrol, respectively. (C) A graph represents quantification of relative protein
levels of HSF1 and CHOP in the three distinct groups of primary cortical neurons (means
± SEM, *P <0.05, ***P <0.001, n = 3-4). TG (1 M, 6 hr) and rapamycin (0.5 M, 6 hr),
(D) Rat primary cultured cortical and hippocampal neurons were treated with
tunicamycin (TM) and TG at different doses (1 M and 5 M) and duration times (6 hr
and 12 hr). (E) Cerebral cortex of 5 month-old B6 mice subjected to the intraperitoneal
injection of thapsigargin (TG, 2 mg/kg) were harvested at different time points indicated
and subjected to western blot. A graph showing the change on the relative protein levels
of HSF1 in the mouse cortex after TG treatment (**P < 0.01, comparing to control
injected with PBS containing 10% DMSO, means ± SEM, n = 5).
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activation in vitro, we transiently transfected N2a neuroblastoma cells with wild-type- or
P301L- or ΔK280-TauRD. Tau protein typically does not form amyloid fibrils in vitro
because of its intrinsic hydrophilic feature. The lack of amyloidogenic propensity can be
overcome by using the tau repeated domain (TauRD), the most commonly used form of
truncated tau. The four conserved sequence motifs in this domain are essential for tau
aggregation. Both eIF2-CHOP activation and decreased HSF1 protein expression were
manifested in ΔK280 TauRD transfected N2a cells (Figure 4-8A). Thus, we generated
N2a cells stably overexpressing TauRD ΔK280 (N2a-TauRD ΔK280) as a cellular model to
study the relationship of CHOP activation and HSF1 loss in the following studies. In
N2a-TauRD ΔK280, about 40 % of HSF1 protein was lost whereas 2.3-fold increase in
CHOP protein was found in N2a-TauRD ΔK280, which was statistically significant
(Figure 4-8B, HSF1, P < 0.01; CHOP, P < 0.05, n = 4). We observed a remarkable HSF1
increase after treatment with each of three agents to inhibit autophagy-lysosome pathway
and MG132, a proteasomal blocker, suggesting that HSF1 protein was degraded by both
UPS and autophagy-lysosome in N2a-TauRD ΔK280 (Figure 4-8C).
Since reduced HSF1 expression caused CHOP activation in the mouse brain
(Figure 4-3), we asked if HSF1 degradation was related with CHOP activation in N2aTauRD ΔK280. Overexpressed HSF1 WT reduced about 60 % of CHOP protein
expression in N2a-TauRD ΔK280 (Figure 4-9A, P < 0.001, n = 4). Conversely, eIF2CHOP activation seemed to further promote HSF1 degradation in N2a-TauRD ΔK280
(Figure 4-9B, P < 0.01, n = 4), as seen in primary neurons in Figure 4. Suppression of
CHOP activation by rapamycin attenuated thapsigargin-induced autophagy-lysosomal
HSF1 degradation in N2a-TauRD ΔK280 (Figure 4-9C). During thapsigargin and
tunicamycin treatments for various time periods, reduction of CHOP expression via
siRNA upregulated HSF protein expression in N2a-TauRD ΔK280 (Figure 4-9D), which
was statistically significant (Figure 4-9E, P < 0.05, n = 4). However, in the absence of
thapsigargin, CHOP was revealed not to be a primary component in HSF1 degradation
present in N2a-TauRD ΔK280, as confirmed by the lack of statistically significant HSF1
change following CHOP silencing (Figure 4-9E).
Aberrant HSF1 Degradation and HSP70 a5 (BiP/GRP78) Attenuation Are
Associated with Tau Accumulation and Toxicity in Tauopathy
HSP70 a5 (BiP/GRP78), a major ER chaperone protein, acts as a negative
regulator of UPR signaling (Bertolotti et al., 2000, Gorbatyuk et al., 2013). The promoter
of HSP70a5 possesses DNA sequences called heat shock elements where HSF1 can bind
for transcriptional activation (Mori et al., 1992). In contrast to CHOP elevation, HSP70
a5 (BiP/GRP78) expression normalized to -actin was slightly reduced in the human AD
brains when compared to non-AD brains (Figure 4-10A, non-significant). In addition, the
steady state level of HSP70 a5 (BiP/GRP78) was 70% less and 60% less in N2a-TauRD
ΔK280 and rTg(tauP301L)4510 than their control, respectively (Figure 4-10B).
Overexpressed HSF1 protein in N2a-TauRD ΔK280 not only significantly
enhanced HSP70 a5 (BiP/GRP78) expression but also remarkably reduced TauRDΔK280
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Figure 4-8. HSF1 Degradation and CHOP Activation in N2a-TauRD ΔK280 Stable
Cell Line.
(A) Western blot analysis on N2a neuroblastoma cells transiently overexpressing GFPtagged repeated domain (RD) tau constructs (TauRD WT, TauRD P301L, TauRD ΔK280)
and empty vector (control). (B) A graph indicates relative protein levels of HSF1 and
CHOP normalized to -actin in N2a and N2a-TauRD ΔK280 stable cell line (means ±
SEM, *P <0.05, **P <0.01, comparing to control, n = 4). (C) HSF1 degradation through
both autophagy-lysosome and proteasome in N2a-TauRD ΔK280. N2a-TauRD ΔK280 were
treated with either autophagy-lysosomal (Baf A1, NH4Cl, CQ) or proteasomal blocker
(MG 132, 20 M) for 6 hr at different concentrations indicated. Left: Control N2a treated
with either MG132 or NH4Cl. Right (short exposure of film): Baf A1: baflomycin A1,
CQ: chloroquine.
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Figure 4-9. HSF1 Degradation Caused by Overexpressed TauRD ΔK280 and
Further Facilitated by eIF2-CHOP Activation.
(A) N2a-TauRD ΔK280 were transfected with either HSF1 WT or HSF1 S303A
(constitutively active form) or empty vector as control. Cleaved-caspase 3 as apoptotic
marker. A right graph represents reduced relative CHOP protein expression levels
normalized to -actin in N2a-TauRD ΔK280 overexpressing HSF1 WT (means ± SEM,
***P < 0.001, comparing to N2a-TauRD ΔK280 transfected with empty vector, n = 4). (B)
N2a-TauRD ΔK280 were treated with either thapsigargin (TG, 1M) for 6 hr or salubrinal
(20 M) for 12 hr or both of them. Their protein lysates were subjected to western blot
(left). A graph on quantitative measurement of the relative HSF1 protein expression
(right, means ± SEM, *P < 0.05, n = 4, N.S., non-significant). (C) Treatment of
thapsigargin (1 M), rapamycin (0.5 M) and NH4Cl (5 mM) in N2a-TauRD ΔK280. (D)
The change on expression levels of HSF1 was assessed in N2a-TauRD ΔK280 transfected
with CHOP siRNA and later subjected to either thapsigargin or tunicamycin (1 M)
treatment for different duration time as indicated. Quantitative measurement of relative
HSF1 protein levels normalized to -actin (bottom, arrow indicates dramatica increase in
HSF1 protein by siCHOP expression.) (E) A graph indicates relative HSF1 protein levels
in N2a-TauRD ΔK280 transfected with CHOP siRNA in the presence or absence of
thapsigargin (means ± SEM, *P < 0.05, N.S., non-significant, n = 3).
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Figure 4-10. The Involvement of Aberrant HSF1 Degradation and HSP70 a5
(BiP/GRP78) Attenuation in Tau Accumulation and Toxicity in Tauopathy.
(A and B) Reduced HSP70 a5 (BiP/GRP78) expression common in human AD brains (A)
and cellular and mouse tauopathy models (B). Graphs show reduction in relative HSP70
a5 (BiP/GRP78) protein expression normalized to -actin in N2a-TauRD ΔK280 ( n = 4, *
P < 0.05), human AD brains (n = 5, non-significant) and rTg(tauP301L)4510 (n = 5, * P
< 0.05). Data represents means ± SEM. actin for Fig. 6B was shown in Fig. 1B and
5A. (C and D) N2a-TauRD ΔK280 were transfected with either HSF1 WT or HSF1 S303A
(constitutively active form) (C) or HSP70 a5 (BiP/GRP78) or BiP siRNA (D). Control
N2a-TauRD ΔK280 transfected with empty vector. (C) A right graph on the relative
HSP70 a5 (BiP/GRP78) and GFP-TauRD protein expression levels normalized to -actin
in N2a-TauRD overexpressing HSF1 WT (means ± SEM, *P < 0.05, HSP70 a5
(Bip/GRP78); **P < 0.01, GFP- TauRD, comparing to control, n = 4). (D) Reduced GFPTauRD accumulation by HSP70 a5 (BiP/GRP78) overexpression in N2a-TauRD ΔK280.
(E) Cell viability in N2a-TauRD ΔK280 overexpressing either HSF1 WT or HSF1 Δ156–
226, or HSP70 a5 (BiP/GRP78) and control was measured by MTT assay (means ± SEM,
*P < 0.05, n = 5)
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(Figure 4-10C, HSP70 a5 (BiP/GRP78), P < 0.05; GFP-TauRD, P < 0.01, n = 4).
Overexpressed HSP70 a5 (BiP/GRP78) reduced TauRD ΔK280 accumulation without
affecting HSF1 protein expression in N2a-TauRD ΔK280 (Figure 4-10D). These
enhanced expressions of HSF1 and HSP70 a5 (BiP/GRP78) led to increased cell survival
in N2a-TauRD ΔK280 (Figure 4-10E). Overexpressed HSF1 mutant (i.e. HSF1Δ156–226)
deficient in trimerization of a prerequisite step for transcriptional activation still
demonstrated increased cell viability, however to a lesser degree than observed in HSF1
WT (Figure 4-10E). In primary neurons and N2a cells (Figure 4-11A, B), in response to
tunicamycin treatment, protective UPR was activated that increased expression of HSP70
a5 (BiP/GRP78) (Figure 4-11A, B, P < 0.05, n = 4). In contrast, this protective stress
response was not elicited in our cellular tauopathy model of N2a-TauRD ΔK280,
supporting attenuated HSP70 a5 (BiP/GRP78) expression in tauopathy (Figure 4-11A, B,
n = 4).
Accumulation of Both -syn and Tau and Increased Activity of Tau Kinases Were
Detected in the Brainstem of HSF1-haploinsufficient Mice
In addition to hippocampus, tau hyperphosphorylation was significantly detected
in the brainstem of HSF1+/- compared to age-matched control mice (Figure 4-12A).
Hyperphosphorylation of -syn at Ser129 is found in Lewy body deposits and its
neurotoxicitiy has been highly implicated in synucleinopathies (Sato et al., 2013). -syn
and its phosphorylation at Ser129 both were found to be upregulated specifically in the
brainstem of HSF1+/- at ~13 months of age, whuch was absent in the hippocampus and
cortex of HSF1+/- (Figure 4-12A). We also observed highly polyubiquitinated -syn in
the brainstem of HSF1+/- (Figure 4-12B). Activation of tau kinases such as glycogen
synthase kinase 3 beta (GSK3) and cyclin-dependent kinase 5 (CDK5) plays a key role
in tau hyperphosphorylation in tauopatheis. Phosphorylation of GSK3 at a distinct site,
Y216, is necessary for its activity. CDK5 is activated by binding to activator protein, p35,
and its cleaved form of p25. Consistent with increased tau phosphorylation, expression of
p35, p25, and p-GSK3Y216) was elevated in the brainstem of HSF1+/(Figure 4-12C). This increased activity of kinases was only detectable in the brainstem,
not in the hippocampus and cortex of HSF1+/-. Protein phosphorylation is normally a
reversible process regulated by phosphatases as well as kinases. In particular, protein
phosphatase 2A (PP2A) is a principal tau-dephosphorylating enzyme in neurons. We did
not observe any change on PP2A expression (Figure 4-12C).
Summary
Here we report studies in human brain and tau pathogenic mouse models
(rTg4510 and PS19), identifying HSF1 degradation and UPR activation as precursors of
aberrant tau pathogenesis. We demonstrate that chemical ER stress inducers caused
autophagy-lysosomal HSF1 degradation, resulting in tau hyperphosphorylation in rat
primary neurons. In addition, permanent HSF1 loss reversely causes chronic UPR
activation, leading to aberrant tau phosphorylation and aggregation in the hippocampus of
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Stress in N2a-TauRD ΔK280.
(A) Primary cortical neurons treated with tunicamycin (TM, 1 µM). (B) N2a-TauRD
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control N2a (means ± SEM, *P < 0.05, N.S., non-significant, n = 4).
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Figure 4-12. Accumulation of Both -syn and Tau and Increased Activity of Tau
Kinases Were Detected in the Brainstem of HSF1+/-.
(A) Protein lysates from mouse brainstem were subjected to western blot to detect p-Tau
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aged HSF1 heterozygous knock-out mice. The deleterious interplay of UPR activation
and HSF1 loss is exacerbated in N2a cells stably overexpressing a pro-aggregation
mutant TauRD ΔK280 (N2a- TauRD ΔK280). We provide evidence of how these two
stress response systems are intrinsically interwoven by showing that the gene encoding
C/EBP-homologous protein (CHOP) activation in the UPR apoptotic pathway facilitates
HSF1 degradation, which likely further contributes to prolonged UPR via ER chaperone
HSP70 a5 (BiP/GRP78) suppression. Attenuating this vicious cycle by genetically or
pharmacologically upregulating HSF1 relieves the tau toxicity in N2a- TauRD ΔK280 by
reducing CHOP and increasing HSP70 a5 (BiP/GRP78). Our work reveals how the
bidirectional crosstalk between the two stress response systems promotes early tau
pathology and identifies HSF1 being one likely key player in both systems.
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CHAPTER 5.

BEHAVIORAL CHARACTERIZATION OF HSF1
HAPLODEFICIENT MOUSE
Introduction

In Chapters 3 and 4, we have studied the critical role of HSF1 protein regulation
in both synucleinopathy and tauopathy by biochemical analyses. We observed significant
aging-associated AD-like neuropathological features, particularly, in the hippocampus of
HSF1 haploinsufficient mouse (HSF1+/-). Expression of molecular chaperons is invovled
in not only tau clearance but also rescuing behavioral deficits in tau transgenic mice (Ma
et al., 2013). Thus, it is reasonable to hypothesize that reduced HSF1 contributes to
neurodeneration and causes behavior deficits in mouse.
There is mounting evidence that the hippocampus plays an essential role in
memory formation. The very first historical evidence came from Henry Molaison, whose
unexpectedly disrupted hippocampus led to amnesia and failure of forming new episodic
memories (Scoville et al., 1957). The hippocampus was first identified to regulate
declarative long-term memory (Eichenbaum et al., 2004). Declarative memory indicates
memory of facts and events that can be consciously recalled. Later, numerous studies
have pointed out the hippocampus as a place responsible for working memory in the
human brain (Axmacher et al., 2007, Poch et al., 2011). Working memory categorized as
short-term memory enables temporary storage and managing the stored information that
are necessary to execute complex tasks. In addition to the hippocampal function in
memory, the hippocampus is involved in anxiety together with the amygdala and
prefrontal cortex (Phillips and LeDoux, 1992, Sanders et al., 2003). The brainstem is a
brain region where we found accumulation both -syn and tau protein in the aged
HSF1+/- (Figure 4-12). The proper function of the the brainstem is necessary for making
coordinated movements of the limbs and for maintaining posture. The brainstem is also
involved in survival-related behaviors such as eating and drinking. The substantia nigra, a
PD-affected area located in the midbrain, plays a key role in the regulation of movement,
reward, and addiction. Taken together, it is intriguing to determine if there is any possible
behavioral change including memory, anxiety, and locomoter activity in HSF1+/-.
Zhu et al., 2008 indicates that HSF1 deficient mice exhibited defective motivation
and decreased exploratory behavior. Later, Uchida et al., 2011 also reports that HSF1
knock out mice showed reduced anxiety levels in a novelty-suppressed feeding test and
an open field test. Using a forced swim test and a sucrose preference test, they
demonstrated enhanced depression-like behavior in HSF1 homozygous knock-out mice.
In the current chapter, we will extend our study to characterize the behaviors of aged
HSF1+/- by performing a set of behavioral assays.
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Results
Aged HSF1-haploinsufficient Mice Exhibit Increased Anxiety Levels in the Elevated
Plus Maze, Not in the Open Field Test
The previous studies from others reported statistically significant change on the
anxiety levels only in HSF1 homozygous knock-out mice, not in heterozygous knock-out
mice, compared to age-matched control mice, in the open field tests (Zhu et al., 2008,
Uchida et al., 2011). Open-field test and elevated plus maze are commonly used to
measure anxiety-like behaviors. In the current study, using open field test, we attempted
to examine anxiety levels in HSF1-haploinsufficient mice (HSF1+/-) at two different
ages, 13 months and 25 months, in comparison with 13 month-old HSF1+/+. In the open
field test, all three groups of mice showed similar levels of total distance (Figure 5-1B).
Total activity was found to be reduced in 25 month-old HSF1+/- compared to the other
groups of mice (Figure 5-1A). In addition, time in center, which can be used as a
measurement of anxiety levels, was increased in both different age groups of HSF1+/- at
almost similar levels (Figure 5-1C). However, all the differences observed were not
statistically significant probably owing to large variation within groups.
In the elevated plus maze, we detected significant difference among groups in
terms of time they spent in either open arm or closed arm or center zone (Figure 5-2B).
Time spent in open arms was reduced in 13 month-old HSF1+/- when compared to
HSF1+/+, which was statistically significant (Figure 5-2B). 25 month-old HSF1+/- spent
more time in closed arms and less time in open arms compared to 13 month-old HSF1+/-,
(Figure 5-2B). The number of entries into open and closed arms, a parameter that
represents locomoter activity of mouse, was increased in HSF1 +/- mice at two different
ages compared to HSF1+/+ (Figure 5-2A).
Aged HSF1-haploinsufficient Mice Exhibit Hippocampal-Dependent Learning and
Memory Deficits
Furthermore, we investigated short-term and long-term memory functions in the
same group of HSF1+/- at two different ages, 13 months and 25 months, in comparison
with 13 month-old HSF1+/+. Mice were tested in three independent behavioral assays,
cross maze, fear contextual memory test, and morris water maze in order. First, the three
groups of mice were subjected to the cross maze where two parameters, total entries and
spontaneous alternation, were measured. The number of total entries as a reflection of
activity was not different among groups (Figure 5-3A). Of note, working memory
determined by spontaneous alteration ratio appeared to be significantly impaired in
HSF1+/- at both ages (Figure 5-3B). We observed no big difference between two groups
of HSF1+/- at different ages (Figure 5-3).
Next, mice were subjected to the fear contextual retrieval test. Context-dependent
memory enables mice to enhance the ability to recall specific information in the condition
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Figure 5-1. Locomoter Activity and Explorative Behavior in the Open Field Test.
(A) Total number of beam breaks indicates locomoter activity. (B) Total distance
travelled (unit : inch) represents locomoter activity. (C) Time spent in center was
measured to assess explorative behavior. Means ± SEM are represented in the graph. n =
10 (HSF1+/+, 13 months), n = 17 (HSF1+/-, 13 months), n = 6 (HSF1+/-, 25 months).
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Figure 5-2. Increased Anxiety-related Behavior in HSF1-haploinsufficient Mice in
the Elevated Plus Maze.
(A) Total number of entries into either open or closed arms. (B) Percentage of time spent
in either open arms or closed arms or center zone was measured to assess anxiety-related
behavior in three groups of mice. Means ± SEM are represented in the graph. * P < 0.05,
** P < 0.01, *** P < 0.001 n = 10 (HSF1+/+, 13 months), n = 17 (HSF1+/-, 13 months),
n = 6 (HSF1+/-, 25 months)
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Figure 5-3. Impaired Working Memory in HSF1-haploinsufficient Mice in the
Cross Maze.
(A) Total number of arm entries in HSF1+/+ (B) Ratios of spontaneous alternation versus
total entry number were calculated. Means ± SEM are represented in the graph. * P <
0.05. n = 10 (HSF1+/+, 13 months), n = 17 (HSF1+/-, 13 months), n = 6 (HSF1+/-, 25
months)
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that contexts exposed at encoding and retrieval are the same. During the first day training
session, behaviors of HSF1 +/- and HSF1+/+ generated similar curves in the graph where
freezing percentage across time was described (Figure 5-4A). A freezing percentage
curve of 25 month-old HSF1+/- was shifted to downward in the graph (Figure 5-4A). As
general, retrieval memory is measured by the freezing percentage on the second retrieval
day. A freezing percentage was slightly increased in 13 month-old HSF1+/- compared to
HSF1+/+, which was further elevated in 25 month-old HSF1+/- (Figure 5-4B). However,
these changes were not statistically significant.
Finally, morris water maze test was employed to investigate learning and memory
function in these mice. A graph that indicates total distance travelled across total 10 days
hidden tests was shifted upward for HSF1+/- mice at 13 months of age compared to
HSF1+/+ (Figure 5-5A). In other words, HSF1+/- tended to travel longer distance until
they reached a platform. Learning and memory appeared likely to be defective in
HSF1+/- at 25 months of age (Figure 5-5A). Reference memory represents learned
performance based on representations that are found to be useful across trials. Reference
memory was significantly reduced in HSF1+/- at 25 months of age (Figure 5-5B).
HSF1+/- and HSF1+/+ showed comparable levels of swimming speed, supporting that
decreased total distance in HSF1+/- was attributable to impairment in learning and
memory as a result of HSF1 haplodeficiency (Figure 5-5C).
Summary
The data obtained from elevated plus maze and open field test in mouse has often
been contradictory. It is desirable to carefully consider all the parameters that possibly
confound the anxiety levels measured in these tests. Time in center, an indicator of
anxiety-related behavior in the open field test, was slightly increased in HSF1+/compared to HSF1+/+ (Figure 5-1). Our results are consistent with the published data
from Uchida et al., 2011. However, there is a possibility that increased locomoter activity
of HSF1+/- might affects the interpretation of time in center in the test (Figure 5-1). In
the elevated plus maze, although the number of total arm entries was upregulated in
HSF1+/-, these mice exhibited significant decrease in the time spent in open arms. Time
spent in open arms was further increased in HSF1 +/- at 25 months of age. It is argued
that open filed test is suitable to measure locomoter and explorative behavirors whereas
elevated plus maze is to evaluate anxiety-like behaviors. Thus, increased anxiety levels
observed from elevated plus maze may be more reliable data than results from the open
field test. Novelty suppressed feeding test can be great alternative to further study
anxiety-related behaviors in HSF1+/-. This test is designed to assess stress-related
anxiety levels by measuring the latency of mouse to eat a familiar food such as sucrose.
Our group previously showed that HSF1+/- spent less time with a novel object
than wild-type control, suggesting impairment of episodic memory associated with the
limbic system including hippocampus in HSF1+/- (Wang et al., 2016). In the current
study, we garnered new evidence of impaired memory associated with damaged
hippocampus in HSF1 +/- by several behavioral tests. Morris water maze and contextual
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Figure 5-4. Fear Acquisition and Contextual Fear Memory in the Contextual
Fear Conditioning Test.
(A) Freezing time (%) during fear acquisition (training) in the contextual fear
conditioning test. (B) Recorded contextual fear retention (context retrieval) 24 hr after
training. Data represents mean ± SEM. n = 10 (HSF1+/+, 13 months), n = 17 (HSF1+/-,
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Figure 5-5. Defective Spatial Learning and Memory in HSF1-haploinsufficient
Mice in the Water Maze.
(A) Distance swam was measured to examine spatial learning and memory in three
different groups of mice. Histogram indicates average distance swam (cm) in cued and
hidden platform sessions. For analysis on hidden platform sessions, distance was
averaged for every two days (total ten days hidden platform session, one block includes
two days) (B) Probe trial test. After hidden platform sessions, percentage of time spent in
the correct quadrant where platform was located was assessed to determine reference
memory. (C) Swimming speed in the last two days of hidden session (block 5) was
measured for three groups of mice. Data represents mean ± SEM; *P < 0.05. n = 10
(HSF1+/+, 13 months), n = 17 (HSF1+/-, 13 months), n = 6 (HSF1+/-, 25 months).
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fear conditioning test are the most commonly used tasks to examine hippocampusdependent long-term memory. Contextual fear acquisition may involve both spatial and
configural memory. Hippocampus is involved in contextual fear conditioning by
affecting the input and output structure in fear conditioning (Phillips and LeDoux, 1992,
Sanders et al., 2003). Amygldala also plays an important role in the formation and
storage of fear memories. Disrupted amygdala caused failure in acquisiting and
expressing fear-related memory (LeDoux et al., 1990). It should be noted that memory
formation is not dependent on a single region, but rather determined by the interaction of
neural circuitury. In the water maze which is a multi-trial task, it is hard to distinguish
between deficits in learning versus memory. HSF1+/- seemed to have a difficulty in
finding a platform compared to its control, which was further exacerbated in 25 monthold HSF1+/-. Because of a lack of statistical significance possibly due to large variation
within each group in the water maze, repeated experiments with sufficient number of
mice per each group need to be performed to consolidate our findings and make a
conclusion. Defective working memory in HSF1+/- in the cross maze test further
strengthens that HSF1 plays a crucial role in the formation and storage of memory related
with functional hippocampus.
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CHAPTER 6.

DISCUSSIONS AND FURTHER DIRECTIONS

Aberrant HSF1 Degradation in Synucleinopathy
Herein we have provided compelling and novel in vitro and in vivo evidence that
proteotoxic stresses, as exemplified by α-synucleinopathy, induce rapid and sustained
HSF1 protein degradation mediated by the E3 ligase NEDD4 through UPS. We show
here that both WT and A53T mutant α-syn caused HSF1 protein degradation to varying
degrees: while A53T α-syn-induced HSF1 lost in both cytosolic and nuclear
compartments, WT α-syn over- expression appeared to only induce loss of nuclear HSF1.
Whether nuclear HSF1 is more vulnerable to proteotoxic stress remains unclear.
The consequences of losing HSF1, a master regulator of stress response for cell
survival, can be detrimental in many ways. For instance, impairment of HSF1-mediated
stress response, reflected by failed induction of chaperone proteins to neuronal stresses
can significantly impact the onset, development, and progression of stress-related
neurodegenerative diseases. Additionally, given that HSF1 is an integrated part of
proteosomal functions, even partial loss of HSF1, can further compromise proteasomal
degradative machinery. This results in a build-up of misfolded substrate proteins that are
labeled to be degraded by UPS (Pirkkala et al., 2000, Anckar et al., 2011). We recently
discovered that HSF1 is the major transcription factor for activating not only hsp genes,
but also a number of genes pertinent to synaptic functions, such as bdnf (Chen et al.,
2014). Therefore, loss of HSF1 is expected to compromise synaptic plasticity and
memory function. Given its various significant functions, loss of HSF1 may underlie a
fundamental mechanism of neurodegeneration, featured by proteinopathies. It should be
noted that HSF1 protein degradation appears to be a process selectively induced by
proteotoxic stress, and not heat stress. In fact, heat stress induces HSF1 activation, and
much of our understanding of HSF1 regulation has derived from the studies under heat
shock conditions on various species: similarly to what an Hsp90 inhibitor does, heat
shock in- duces an initial releasing step of HSF1 sequestration from Hsp90, followed by a
series of phosphorylation, trimerization and nuclear translocation (Lindquist et al., 1986,
Cotto et al., 1998, Zou et al., 1998, Shi et al., 1998, Morimoto et al., 1998). Multiple
post-translational modifications of HSF1 have been studied in relation to its activity state,
including acetylation, sumoylation and phosphorylation (Neef et al., 2011), and we can
now add ubiquitination to that list.
Proteostasis has been most widely studied under heat shock conditions, and this
HSR most notably concerns the HSF1 complex (Pirkkala et al., 2000). Proteostasis under
proteotoxic stress, while less exten- sively studied, is believed to share much in common
as HSR. However, it remains unclear how misfolded proteins are targeted for proteolysis
under these conditions. Recently, Rsp5 and its mammalian homolog NEDD4 were
discovered as the E3 ligases responsible for the increased ubiquitylation induced by heat
stress. These ligases mainly target cytosolic misfolded proteins upon heat shock for
proteasome degradation (Fang et al., 2014, Haitani et al., 2006). Interestingly,
temperature-sensitive Rsp5 mutants revealed dysfunctional HSF1 transcriptional activity,
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as well as reduced protein expression of HSF1, conceivably due to some kind of posttranslational modification(s) (Haitani et al., 2008). In addition, physical interactions
between Rsp5 and HSF1 were detected under this experimental condition. This work
provided evidence of a modulatory role of Rsp5, as in its regulation of HSF1 during
mRNA export from nucleus (Tardiff et al., 2013); however, it did not provide direct
support for Rsp5 being the E3 ligase.
Herein, we provide compelling biochemical evidence for NEDD4 as the E3 ligase
for HSF1 ubiquitination and the subsequence degradation via UPS. NEDD4 is the
prototypic HECT- type E3 ligase for a large family that has been conserved from yeasts
(Rsp5) to humans. NEDD4 was first identified by genetically screening developmentally
down-regulated genes in the early embryonic, murine central nervous system (Yang et
al., 2010, Donovan et al., 2013). Human NEDD4 exists in at least eight isoforms,
resulting from alternative splicing that recognizes a proline-rich motif (PPxY or PY
motif) not present in the HSF1 protein.
Strangely enough, NEDD4 was also reported to be the E3 ligase of α-syn in
Parkinsonism via the endosomal–lysosomal pathway (Tofaris et al., 2011). Defective
Rsp5/NEDD4 pathways were linked to α-synucleinopathy, which was supported by
genetic screening in yeast (Tardiff et al., 2013, Chung et al., 2013). We consistently
found that overexpression of WT NEDD4, but not the DN mutant form, resulted in a
significant reduction of both ROS and α-syn aggregation (Figure 3-6A, B). The
seemingly contradictory roles of NEDD4 in the degradation processes of both toxic α-syn
and protective HSF1 raise possibility of involving different mechanisms. Although our
current in vitro data suggest that HSF1 is primarily degraded via UPS, we cannot rule out
possible involvement of other major lysosomal path- ways, particularly the chaperonemediated autophagy (CMA). In addition, different isoforms of NEDD4 may ubiquitinate
α-syn and HSF1, subjecting them to different subcellular compartments that likely
involve different co-chaperone networks. Nevertheless, our study seeks to identify
NEDD4 as an important E3 ligase, much like the C-terminus of Hsc70-interacting protein
and Parkin in neurodegeneration.
Protein acetylation/deacetylation has been recently linked to protein regulation,
especially via complex interplay with other forms of post-translational modifications
(Caron et al., 2005). K208 and K298 acetylation by the acetyltransferase EP300 has been
reported to regulate HSF1 protein stability under heat stress during reorgan- ization of
nuclear proteosomal network (Raychaudhuri et al., 2014). Although it may be
coincidental, acetylation has recently been identified as a mechanism regulating tau
turnover (Cook et al., 2014), implying that complex interplay between different posttranslational modifications represents a common mechanism neurons use to fine-tune
major classes of molecular processes. Our study distinguishes a strong correlation
between an increased acetylation of HSF1 and its degradation, which is contrary to the
relationship identi- fied between acetylation and the degradation of FTDP tau (Min et al,
2010). Deacetylation of Lys 80 residue by SIRT1 activation has been shown to activate
the transcriptional activity of HSF1 via assessing its promoter occupancy rate
(Westerheide et al., 2009). We demonstrate that the same Lys 80 acetylation state directly
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correlates with the ubiquitination levels and the stability of HSF1. The underlying
mechanism is unclear. Since we observed opposite levels of ubiquitination on the K80R
but not K80Q mutants, ubiquitination of HSF1 unlikely occurs on the Lys80. However, it
is plausible that somehow highly acetylated Lys80 (e.g. K80Q) alters protein conformation, making it more accessible for NEDD4-mediated ubiquitination.
In summary, we discovered complete loss of HSF1 protein under various
conditions of proteinopathies, suggesting that aberrant HSF1 protein degradation may
represent a common and important key molecular mechanism underlying neurodegeneration. While HSF1 is increasingly being recognized as an important therapeutic target
(Neef et al., 2011), it should be approached with caution, and HSF1’s protein degradation
should be taken into consideration. Pharmacological development of a feasible HSF1
stabiliing agent is thus of high importance. It can perhaps be used in combination with an
HSF1-activating agent to combat neurodegeneration. Our study has also demonstrated the
potential sig- nificance of SIRT1-mediated deacetylation in HSF1 stability, adding to the
growing body of evidence of sirtuins in the regula- tion of proteostasis (SampaloMarques et al., 2015). Fully delineating the underlying mechanism of SIRT1-mediated
proteostasis will facilitate development of this promising strategy.
HSF1 Degradation as a Mechanistic Link between UPR Activation and Tau
Phosphorylation
Here we provide both in vitro and in vivo evidence that strongly suggests an autopropagating interplay of UPR activation and HSF1 degradation being a common
pathogenic feature in both human AD and tau transgenic mouse AD models (Figure 6-1).
Characterizations of ER stress on early-stage AD / MCI patients have been neglected in
many studies. The underlying mechanisms leading to chronically sustained ER stress in
human AD brain are not entirely understood. This experiment looks to identify persistent
and striking HSF1 degradation as an integral component in the chronic UPR activation
pathway that ultimately causes tau hyperphosphorylation in early AD pathogenesis.
It should be noted that proteotoxic stress from tau aggregation could promote destabilization of HSF1 protein in several ways that are not clearly understood (Figure 4-1,
4-8). We implicate CHOP activation in the UPR pathway as one of key players that
partially contributes to HSF1 degradation in tauopathy (Figure 4-7, 4-9). CHOP
activation can be regulated in the ER not only by PERK-eIF2 but also by IRE1 or other
unknown ER-independent mechanism (Kato et al., 2012). Consequently, reduced steady
state level of HSF1 is likely to trigger permanent PERK-CHOP activation (Figure 4-3)
that reversely facilitates HSF1 loss, leading to tau hyperphosphorylation in tauopathy
(Figure 4-3, 4-9A). It can therefore be reasonably concluded that suppression of proapoptotic protein CHOP could be an efficient means of protecting HSF1 from ER stressrelated tauopathy. However, it was also revealed that in the young HSF1+/- mouse brain,
HSF1 depletion alone was insufficient to cause either ER stress or tau phosphorylation
(Figure 4-4), but another unidentified aging-related pathway with which HSF1
degradation associates with may actually cause disturbances in ER homeostasis. The
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Figure 6-1. Hypothetic Model on a Vicious Cycle of UPR Activation and HSF1
Degradation in Tauopathy.
(A) Acute ER stress activates both CHOP and BiP proteins, which may ‘transiently’ lead
to HSF1 degradation (Figure 4-4) and tau phosphorylation. Activated BiP contributes to
cease UPR activation. (B) Chronic UPR activation (CHOP activation and BiP
attenuation) in tauopathy. Persistent HSF1 loss seemed to cause chronic CHOP activation
(Figure 4-2, 4-3), starting to form a vicious cycle of chronic CHOP activation and
persistent HSF1 degradation. This eventually may lead to the formation of aberrantly
phosphorylated tau aggregates in the aged hippocampus (Figure 4-2, 4-3). HSP70 a5
(BiP/GRP78) attenuation may contribute to tau accumulation and its toxicity in tauopathy
(Figure 4-6). (Red, UPR-related proteins; Blue, HSF1-regulated proteins).
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relevant kinase(s) affecting tau phosphorylation in CHOP-HSF1 axis should also be
determined in further studies. In addition to the role of autophagy-lysosomal activity on
the HSF1 protein turnover, given highly poly-ubiquitinated HSF1 protein in N2a-TauRD
ΔK280, it is necessary to investigate the involvement of ubiquitin-proteasome system in
tauopathy as we did in synucleinopathy (Kim et al., 2016). Tau toxicity can impair
another essential response in ER called Endoplasmic-reticulum-associated protein
degradation (ERAD) (Abisambra et al., 2013). Hrd1 is an ERAD-associated E3 ubiquitin
protein ligase previously found to interact with tau (Abisambra et al., 2013). We observed
a tremendous decrease in Hrd1 expression in rTg4510 (data not shown). The potential
interactions between ERAD and HSF1 should be considered in future studies.
Considering HSF1 loss observed in Braak III/IV stages, it also leaves open the
possibility of the involvement of amyloid pathology in HSF1 degradation. We found that
the extent of HSF1 loss was more severe in tau transgenic mice (Tg4510) than in APP
transgenic mice (Tg2576) that produced amyloid beta plaques (Wang et al., 2016)
(Figure 4-1). Tg2576 mice were reported not to show any signs of UPR activation by
others (Lee et al., 2010). However, the more recent in vitro data suggests possible
involvement of UPR activation in A toxicity (Resende et al., 2008). It is thus necessary
to identify whether A can cause ER stress in vivo, and if so, whether or not this
mechanism is tau-dependent.
Another corollary of HSF1 loss represented in the study is that it can be
deterministic of the balance between pro-apoptotic (CHOP) and pro-survival responses
(BiP) to ER stress. Inhibited HSP70 a5 (BiP/GRP78) protein expression is consistently
observed in all our tauopathy models (N2a-TauRDΔK280, rTg(taupP301L)4510, and
human AD, Figure 4-10). It may lead to an inability to attenuate UPR (Bertolotti et al.,
2000, Gorbatyuk et al., 2013), contributing to tau aggregation and its toxicity in
tauopathy. In vivo studies on Tau ΔK280 transgenic mice indicated that tau toxicity was
closely related to its ability to form aggregates (Mocanu et al., 2008). We could garner
some evidence to speculate that the highly aggregated fibrillary form of tau is the major
causative species to induce HSF1 degradation. Overexpressed full-length Tau WT, Tau
P301L, and Tau R406W in N2a cells did not significantly alter HSF1 protein levels.
Each tau repeated domain only (TauRD) and the mutant tau transgene lacking N-terminal
insert (expressed in rTg4510) are all considered to aggregate faster than full length tau
and the mutant tau transgene including one N-terminal insert (expressed in PS19),
respectively (Barghorn et al., 2000, Binder et al., 2005, Gustke et al., 1994, VogelsbergRagaglia et al., 2000). The extent of HSF1 degradation may explain the discrepancies that
exist in the presence of UPR activation in different tau transgenic mouse models (Shipton
et al., 2011) (Figure 4-1).
The consequence of eIF2 phosphorylation appears to be biphasic (Chadwick et
al., 2012, Drexler et al., 2009). Though salubrinal is known to inhibit ER stress via
protein synthesis attenuation (to prevent ER protein overload) (Boyce et al., 2005),
elevated p-eIF2by salubrinal rather facilitated UPR-induced HSF1 degradation in N2aTauRD ΔK280 of our study (Figure 4-9). Therefore, furthermore comprehensive
consideration of both pathways and their functional outcomes in the cellular context is
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required. Our results are informative of the caution that should be taken in future designs
of therapeutic approaches seeking to treat neurodegenerative diseases amenable to UPR
inhibition.
Synaptic Tau Pathology and HSF1 Dysregulation
Interestingly, tau protein originally thought to be located in axon is now found to
be present in dendritic spines as well, where it interacts with the Src kinase Fyn to
regulate the NMDA receptor-mediated synaptic signaling (Ittner et al., 2010). Nonreceptor tyrosine kinase Fyn located in the postsynaptic density phosphorylates NMDA
receptor subunit NR2B, leading to increase in the expression and activity of NMDA
receptor. Tau protein mediates the translocation of Fyn to the exciatotory synpases (Ittner
et al., 2010). In contrast, P301L mutant human tau was previously shown to reduce the
number of glutamate receptors in spines, disrupting synaptic function (Hoover et al.,
2010). Accumulation of tau in the somatodedritic and synaptic compartments in AD
mouse models has been identified (Tashiro et al., 1997, Hoover et al., 2010). The
presence of phosphorylated tau at synapses was not limited to human AD brain but also
found in the adult human brain (Tai et al., 2012). In addition to its involvement in the
microtubule stabilization, the normal physiological functions of synaptic tau in neurons
should be further elucidated in detail. Tau deletion resulted in preventing hippocampaldependent behavior deficits in the AD mouse model overexpressing APP, revealing a
central role of tau in cognitive impairment in AD (Roberson et al., 2007). Proper function
of proteasome mediated protein turnover appears to be critical for synaptic transmission
and plasticity on a time scale of minute (Speese et al., 2003). There is one study
suggesting that synaptic tau aggregates were highly associated with impaired proteolysis
through UPS (Tai et al., 2012). Rather than A, tau protein well correlated with UPS
impairment in synaptosomes in human AD brain. Attenuating tau-driven proteasome
dysfunction prevented cognitive deficits in tau transgenic mouse model (Myegu et al.,
2016). Therefore, impaired UPS function may be one potential mechanism by which
synaptic tau causes cognitive deficits.
Neuronal hyperexcitability has been linked to both amyloid and tau pathology in
AD mouse models (Busche et al., 2012). Neuronal activity has been implicated in the
propagation of tau pathology (Wu et al., 2016, Pooler et al., 2013). Optogenetically
stimulated rTg4510 mice overexpressing P301L human tau exacerbated somatic tau
accumulation in the stimulated hippocampus (Wu et al., 2016). Exosomes represent small
extracellular vesicles, which can be secreted and taken up by the recipient cells. Thus, it
has emerged as a novel intercellular communication method to be used for the delivery of
molecules (Asai et al., 2015, de Calignon et al., 2012). In attempts to understand transsynaptic transmission of tau, the concept of exosome-mediated tau transmission was first
conceived by Saman et al., 2012. In the scenario, exosomes containing tau are released
from axonal terminals where they can be taken up by relevant neurons in the neural
circuit. Exosomes travelling to axon are finally released again at the presynaptic
terminals, which contributes to the distribution of tau protein throughout the affected
brain regions. In rat primary cortical neurons, it was demonstrated that neuronal activity
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induced release of tau-containing exosomes, which was dependent on synaptic
connectivity (Pooler et al., 2013). Takeda et al., 2015 provided the first demonstration
that a unique high-molecular weight tau is a specific form of tau involved in tau
propagation throughout the brain. Accumulation of this high-molecular species was
found in the cerebrospinal fluid of AD patients.
Importantly, we could garner substantial evidence that HSF1 plays a crucial role
in the synaptic proteome in neurons. In the current study, we observed not only
abnormally hyperphosphorylated tau protein present in synapses but also hippocampal
memory deficits in HSF1+/-. It is pertinent to explore the possible role of UPS
impairment in both tau accumulation and behavior deficits in HSF1+/-. HSF1 has been
identified to be an important regulator of synaptic genes such as PSD-95 and BDNF. Of
note, boosting HSF1 activity appears to provide synaptic protection in the AD mouse
model by affecting coherent neuronal activity between the PFC and CA1 (Wang et al.,
2016). It might be necessary to assess the electrophysiological features of neurons in
HSF1+/- in future studies.
The current study on the role of HSF1 dysregulation in neurodegeneration just
began to highlight the importance of HSF1 protein stability to protect the brain from
accumulation of misfolded proteins. This work reveals the pathological role of HSF1
degradation in both synucleinopathy and tauopathy. We observed that HSF1
haploinsufficiency in the brain could initiate neuropathological and behavioral changes
that are associated with aging. It is necessary to identify the specific pathway targeted by
aging that likely exacerbates defects as a result of HSF1 loss in the brain. AD has been
featured as a supratentorinal disease and Braak staging of NFTs does not count for the
braintem. However, interestingly, the case of braak stage 0 without any cortical tangles
formation was shown to have NFTs in the dorsal raphe nucleus in the brainstem
(Grinberg et al., 2009). This may suggest that NFTs burden could take place in the
brainstem even before the supraentorhinal region. As each neurodegenerative disease
targets particular subpopulation of neurons, we observed regionally specific pathologic
findings in the brain of HSF1+/-. The findings on the brain stem of HSF1+/- where both
pathological forms of-syn and tau were enormously accumulated should be further
consolidated to make a firm conclusion. If it turns out to be true that brainstem is the
foremost and utmost targeted area by HSF1 deficiency in terms of protein aggregates, it
is intriguing to study the pathological synergistic effects of -syn and tau. It remains as a
challenging task to uncover the direct and indirect cellular pathways that HSF1 loss
activates or suppresses to increase intracellular aggregates in the brainstem
.
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